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1.INTRODUCTION 
Diabetes is a serious, chronic disease that occurs either when the 
pancreas does not produce enough insulin (a hormone that regulates blood 
glucose), or when the body cannot effectively use the insulin it produces. 
Raised blood glucose, a common effect of uncontrolled diabetes, may, over 
time, lead to serious damage to the heart, blood vessels, eyes, kidneys and 
nerves. More than 400 million people live with diabetes. There are four types 
of diabetes mellitus, theyareType-1diabetes (previously known as insulin-
dependent, juvenile or childhood-onset diabetes), Type2 diabetes (formerly 
called non-insulin-dependent or adultonset diabetes), Gestational diabetes 
(GDM) is a temporary condition that occurs in pregnancy and carries longterm 
risk of type 2 diabetes and MODY (Maturity onset Diabetes of the young)1. 
Globally, an estimated 422 million adults are living with diabetes 
mellitus, according to the latest 2016 data from the World Health Organization 
(WHO)2. Diabetes prevalence is increasing rapidly; previous 2013 estimates 
from the International Diabetes Federation put the number at 381 million 
people having diabetes3. The number is projected to almost double by 
2030.Type 2 diabetes makes up about 85-90% of all cases. Increases in the 
overall diabetes prevalence rates largely reflect an increase in risk factors for 
type 2, notably greater longevity and being overweight or obese2. 
Long standing diabetes mellitus leads to multiple organ damage and it  
is associated with an increased prevalence of microvascular disease 
(Nephropathy, Neuropathy& Retinopathy) and macro vascular diseases 
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(Peripheral vascular disease, Ischemic heart disease& Stroke). Poor glycemic 
control, a factor that has been observed in the Indian population with diabetes 
put them at risk of complication including neuropathy-24.6%, cardiovascular 
disease-23.6%, kidney problem-21.1%, retinopathy- 16.6% and foot ulcer-
5.5%4. 
Globally diabetic neuropathy affects approximately 132 million people 
as of 2010 (1.9% of the population).Diabetes is the leading known cause of 
neuropathy in developed countries, and neuropathy is the most common 
complication and greatest source of morbidity and mortality in diabetes. It is 
estimated that neuropathy affects 25% of people with diabetes. Diabetic 
neuropathy is implicated in 50–75% of nontraumatic amputations. 
The main risk factor for diabetic neuropathy is hyperglycemia. In the 
DCCT (Diabetes Control and Complications Trial, 1995) study, the annual 
incidence of neuropathy was 2% per year but dropped to 0.56% with intensive 
treatment of Type 1 diabetics. The progression of neuropathy is dependent on 
the degree of glycemic control in both Type1 and Type2 diabetes. Duration of 
diabetes, age, cigarette  smoking, hypertension, height, and hyperlipidemia 
are also risk factors for diabetic neuropathy5. Diabetic neuropathy is a 
complication of diabetes in which nerves are damaged due to long-term high 
levels of blood sugar or hyperglycemia. Diabetic neuropathy can affect many 
parts of the body including the legs, feet, bladder, heart, gastrointestinal 
system, and reproductive system. Diabetic neuropathy generally develops 
slowly over a period of months as ongoing high blood sugar levels damage 
the nerves of the body. Symptoms of diabetic neuropathy can include a 
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sensation of pain, numbness, tingling, or prickling that begins in the feet. In 
later stages of diabetic neuropathy, the hands can be affected as well. 
In some cases of diabetic neuropathy, the abnormal sensations can extend to 
the arm, legs and trunk6.  
Several medications are used to relieve nerve pain, but they don't work 
for everyone and most have side effects that must be weighed against the 
benefits they offer. There are also a number of alternative therapies, such as 
capsaicin cream (made from chili peppers), physical therapy or acupuncture, 
that may help with pain relief medications.  Anti-seizure medications drugs 
such as gabapentin (Gralise, Neurontin), pregabalin (Lyrica) and 
carbamazepine (Carbatrol, Tegretol) Tricyclic antidepressant  drugs such as  
amitriptyline, desipramine (Norpramin)  and  imipramine (Tofranil), serotonin 
and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine 
(Cymbalta), can relieve pain with fewer side effects7. 
NATURALHERBES FOR THE TREATMENT OF DIABETIC NEUROPATHY 
 Various herbal remedies for diabetic neuropathy described in the 
ancient healthcare system of India. These herbs are effective in restoring the 
sensation in feet, healing the ulcers and keeping the sugar levels under 
control without causing any side effects. The herbs act together to keep 
nourishing the nerves damaged by diabetic neuropathy. These herbal 
remedies are combination of various herbal supplements which are otherwise 
useful in many other ailments like sexual weakness, erectile dysfunction, lack 
of stamina and strength, ageing related problems. The herbs can also be 
used by females to restore libido, fatigue, general weakness and pain in the 
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calf muscles due to diabetic neuropathy as well as high sugar levels8. The 
herbs are totally natural without any preservatives or chemicals. The herbs 
like Plecospermum spinosum9 Ashwagandha, Chandraprabha Vati, Shilajit, 
Indian gooseberry, Turmeric, Flaxseed oil, Ginger, Fennel seed, Castorl 
oil,Holy basil, Jamun and Fenugreek, Bitter melon, Ginseng, Cayenne 
Pepper, cinnamon and Bilberry leaves. Above herbs for diabetic neuropathy 
may be alleviate or decrease the symptoms of neuropathy. 
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2. REVIEW OF LITERATURE 
2.1 DIABETES: 
Diabetes is a disease that affects body ability to produce or use insulin. 
Insulin is a hormone. When body turns the food into energy (also called sugar 
or glucose), insulin is released to help transport this energy to the cells. 
Insulin acts as a “key”. Its chemical message tells the cell to open and 
receive glucose. If body produce little or no insulin, or are insulin resistant, too 
much sugar remains in blood. Blood glucose levels are higher than normal for 
individuals with diabetes10. All types of diabetic patients insulin dependent 
diabetes mellitus (IDDM), non-insulin dependent diabetes mellitus (NIDDM) 
and secondary diabetes patients can develop neuropathy11. 
2.1.1 COMPLICATINS OF DIABETES:  
Long term complication of diabetes develop gradually. The longer have 
diabetes and less controlled blood sugar the higher the risk of complications. 
Eventually diabetic complications may be disabeling or even life threatening. 
 
Fifgure No: 1 : Complications of diabetes. 
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The most common long term complication diabetes divided into 
macrovascular and microvascular Macrovascular complications include 
damage to the large blood vessels of heart, brain and legs. Microvacular 
complications include damage to the small blood vessels causing problem in 
the eyes, kidneys, feet and nerves. 
Other parts of body can also be affected by diabetes including the 
digestive system, the skin, sexual organs, teeth and gums and the immune 
system12. 
2.2 MACROVASCULAR DISEASE: 
The common macrovascular disease are cardiovascular disease (in the 
heart). cerebrovascular disease (in the brain), and peripheral vascular 
disease (in the limbs)13. 
2.2.1 Cardiovascular disease: 
Diabetes dramatically increases the risk of various cardiovascular 
problems including coronary artery with chest pain(angina), heart attack, 
stroke and narrowing of arteries(atherosclerosis), blood vessel diseases. The 
risk is greater for people with diabetes, who often have increased cholesterol, 
blood pressure levels. Smoking having a family history of cardiovascular 
disease being inactive also increase the risk14. 
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2.2.2 Cerebrovascular disease: 
Cerebrovascular disease is a vascular disease of the cerebral 
circulation. Arteries supplying oxygen to the brain are affected resulting in one 
of a number of cerebrovascular diseases15. It occurs when high cholesterol 
level, together with inflammation in the arteries of the brain. cause cholesterol 
buildup in the vessel are a thick , waxy plaque that can narrow and block 
blood flow in the arteries16. Cerebrovascular transient ischemia attacks(TIAS), 
which often herald a completed stroke, are also more common among 
patients with diabetes17.    
2.2.3 Peripheral vascular disease: 
A condition in which the arteries in the legs, and sometimes  the 
arms18. Peripheral vascular disease 20 times more common in people with 
diabetes than in the general population. Along with diabetes, other risk factor 
for peripheral vascular disease are smoking, inactivity and high blood lipid 
levels (cholesterol and triglyceroids). In people with diabetes chronic high 
blood glucose raises the risk of developing peripheral vascular disease. 
2.3 MICROVASCULAR DISEASE: 
Microvascular complications include damage to eyes (retinopathy) 
leading to blindness, to kidneys (nephropathy) leading to renal failure and to 
nerves (neuropathy) leading to impotence and diabetic foot disorders (which 
include severe infections leading to amputation)19. 
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2.3.1 Diabetic retinopathy: 
Diabetic retinopathy is a leading cause of blindness and visual 
disability. It is caused by small blood vessel damage to the back layer of the 
eye, the retina, leading to progressive loss of vision, even blindness. 
2.3.2 Diabetic nephropathy: 
Diabetic kidney disease is also caused by damage to small blood 
vessels in the kidneys. This can cause kidney failure, and eventually lead to 
death. In developed countries, this is a leading cause of dialysis and kidney 
transplant. 
2.3.3 Diabetic neuropathy: 
Diabetes causes nerve damage through different mechanisms, 
including direct damage by the hyperglycemia and decreased blood flow to 
nerves by damaging small blood vessels. This nerve damage can lead to 
sensory loss, damage to limbs, and impotence in diabetic men. It is the most 
common complication of diabetes. 
2.4 NEUROPATHY:    
Neuropathy the medical term for a condition in which there are 
problems with nerves in the body either they have been damaged or are 
affected by a disease. Usually, neuropathy affects the peripheral nervous 
system rather than the central nervous system (brain and spine)20. 
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Fig.No.2 Difference between healthy nerve cell and damaged cell   
In the peripheral nervous system, there are three primary types of nerves: 
 Sensory nerves control the senses and the body's interpretation of 
different sensations. 
 Motor nerves control muscle movement and power. 
 Autonomic nerves control bodily systems like the gastrointestinal and 
urinary systems. 
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2.4.1 Complication of Diabetic Neuropathy: 
Diabetic neuropathy can cause a number of serious complications, including: 
 Loss of a limb. 
 Charcot joint.  
 Urinary tract infections and urinary incontinence. 
 Hypoglycemia unawareness. 
 Low blood pressure. 
 Digestive problems. 
 Sexual dysfunction. 
 Increased or decreased sweating 
2.4.2 Types of Neuropathy:  
Diabetic neuropathy can be broken into several types. This is because 
we have different kinds of nerves in our bodies that serve different 
functions. The symptoms and treatments depend on which type of diabetic 
neuropathy21. 
There are four types of diabetic neuropathy:                                                                                                
 Peripheral neuropathy (also called diabetic nerve pain and distal          
polyneuropathy) 
 Proximal neuropathy (also called diabetic amyotrophy) 
 Autonomic neuropathy 
 Focal neuropathy (also called mononeuropathy) 
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Peripheral Neuropathy:  
Peripheral neuropathy refers to the conditions that result when nerves 
that carry messages to and from the brain and spinal cord from and to the rest 
of the body are damaged or diseased22. Peripheral diabetic neuropathy goes 
by various names peripheral diabetic nerve pain and distal polyneuropathy. 
Peripheral neuropathy can affect one nerve (mononeuropathy), two or more 
nerves in different areas (multiple mononeuropathy) or many nerves 
(polyneuropathy)23. It may be chronic (a long-term condition where symptoms 
begin subtly and progress slowly) or acute (sudden onset, rapid progress, and 
slow resolution)24-26. The peripheral nerves make up an intricate network that 
connects the brain and spinal cord to the muscles, skin, and internal organs. 
Peripheral nerves come out of the spinal cord and are arranged along lines in 
the body called dermatomes. Typically, damage to a nerve will affect one or 
more dermatomes, which can be tracked to specific areas of the body. Damage 
to these nerves interrupts communication between the brain and other parts of 
the body and can impair muscle movement, prevent normal sensation in the 
arms and legs, and cause pain22. 
Proximal Neuropathy:  
 Proximal neuropathy can also be called diabetic amyotrophy. That myo 
in the word means muscle, so this is a form of neuropathy that can cause 
muscle weakness. It specifically affects the muscles in the upper part of your 
leg(s), buttocks, and hips27.  
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Sometimes, proximal neuropathy can also involve nerve pain, 
especially pain that shoots from the low back and down the leg28. The 
technical medical term for that is radiculopathy, although most people refer to 
it as sciatica. If there’s also shooting nerve pain involved, this form of 
neuropathy can also be called polyradiculopathy-diabetic amyotrophy. 
Proximal neuropathy is the second most common type of diabetic neuropathy 
(second only to peripheral diabetic neuropathy). It usually affects elderly 
people with diabetes; as opposed to peripheral neuropathy, it usually resolves 
with time or treatment21. 
AUTONOMIC NEUROPATHY: 
Autonomic neuropathy is a group of symptoms that occur when there is 
damage to the nerves that manage every day body functions such as blood 
pressure, heart rate, sweating, bowel and bladder emptying, and digestion29. 
Autonomic neuropathy may be seen with Alcohol abuse, diabetes (diabetic 
neuropathy), disorders involving scarring of tissues around the nerves, 
Parkinson disease, Spinal cord injury, Surgery or injury involving the nerves30. 
The first objective of management of a patient with autonomic neuropathy is 
to administer specific treatment for treatable conditions. For example, if an 
autoimmune neuropathy is present, attempted management with 
immunomodulatory therapies should be considered31.  
Focal Neruopathy:  
Focal neuropathy by contrast, affects one specific nerve It’s focused 
neuropathy and also called mononeuropathy. Focal neuropathy which comes 
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on suddenly, most often affects nerves in the head (especially ones that go to 
the eyes). It can also affect the torso and legs. The diabetic patients are also 
susceptible to a variety of asymmetric and focal neuropathies32.  
Types of focal neuropathy: 
a. Cranial neuropathy 
b. Truncal neuropathy 
c. Entrapment neuropathy    
a. Cranial Neuropathy :  
When nervous in the brain (or) brain stem affected areas like face and 
eyes. It is called cranial neuropathy33. The cranial nerve control such a 
function as vision, hearing, facial movement and the actions of some of the 
organs in the head chest and abdomen33. Third, fourth, and sixth cranial 
nerves are commonly involved. Elderly patients are the most affected. Two 
specific types of cranial neuropathy are optic neuropathy and auditory 
neuropathy. Optic neuropathy refers to damage or disease of the optic nerve 
that transmits visual signals from the retina of the eye to the brain. Auditory 
neuropathy involves the nerve that carries signals from the inner ear to the 
brain and is responsible for hearing34. 
b. Truncal Neuropathy :  
Symptomatic truncal polyneuropathy though less common, tends to 
occur in the setting of long standing diabetes with other microvascular 
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complications especially peripheral neuropathy35. Truncal neuropathy is an 
important cause of chest and abdominal pain36. It is also called as 
thoracoabdominal neuropathy, thoracia poly rediculopathy, truncal 
mononeuropathy. On examination, hypoaesthesia or hyperaesthesia may be 
present in the appropriate thoracic segment and abdominal muscle weakness 
leading to abdominal swelling37. 
C. Entrapment neuropathy :  
Nerve compression syndrome or compression neuropathy, also known 
as entrapment neuropathy, is a medical condition caused by direct pressure 
on a nerve.38 It is known colloquially as a trapped nerve, though this may also 
refer to nerve root compression (by a herniated disc, for example). Its 
symptoms include pain, tingling, numbness and muscle weakness. The 
symptoms affect just one particular part of the body, depending on which 
nerve is affected39. 
2.4.3 CAUSES AND PATHOGENESIS OF DIABETIC NEUROPATHY:  
Causes of diabetic neuropathy: 
 Diabetes: Diabetes is the condition most commonly associated with 
neuropathy. The characteristic symptoms of peripheral neuropathy often seen 
in people with diabetes are sometimes referred to as diabetic neuropathy. The 
risk of having diabetic neuropathy rises with age and duration of diabetes. 
Neuropathy is most common in people who have had diabetes for decades 
and is generally more severe in those who have had difficulty controlling their 
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diabetes, or those who are overweight or have elevated blood lipids and high 
blood pressure40. 
 Vitamin deficiencies: Deficiencies of the vitamins B12 and folate as 
well as other B vitamins can cause damage to the nerves. 
 Autoimmune neuropathy: Autoimmune diseases such as rheumatoid 
arthritis, systemic lupus, and Guillain-Barre syndrome can cause 
neuropathies. 
 Infection: Some infections, including HIV/AIDS,  Lyme disease, 
leprosy, and syphilis, can damage nerves. 
 Post-herpetic neuralgia: Post-herpetic neuralgia, a complication 
of shingles (varicella-zoster virus infection) is a form of neuropathy. 
 Alcoholic neuropathy: Alcoholism is often associated with peripheral 
neuropathy. Although the exact reasons for the nerve damage are unclear, it 
probably arises from a combination of damage to the nerves by alcohol itself 
along with the poor nutrition and associated vitamin deficiencies that are 
common in alcoholics. 
 Genetic or inherited disorders: Genetic or inherited disorders can 
affect the nerves and are responsible for some cases of neuropathy. 
Examples include Friedreich's ataxia and Charcot-Marie-Tooth disease. 
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 Amyloidosis: Amyloidosis is a condition in which abnormal protein 
fibers are deposited in tissues and organs. These protein deposits can lead to 
varying degrees of organ damage and may be a cause of neuropathy. 
 Uremia: Uremia (a high concentration of waste products in the blood 
due to kidney failure) can lead to neuropathy. 
 Toxins and poisons can damage nerves. Examples include, gold 
compounds, lead, arsenic, mercury, some industrial solvents, nitrous oxide, 
and organophosphate pesticides. 
 Drugs or medication: Certain drugs and medications can cause nerve 
damage. Examples include cancer therapy drugs such as vincristine 
(Oncovin, Vincasar), and antibiotics such as metronidazole (Flagyl), 
and isoniazid (Nydrazid, Laniazid). 
 Trauma/Injury: Trauma or injury to nerves, including prolonged 
pressure on a nerve or group of nerves, is a common cause of neuropathy. 
Decreased blood flow (ischemia) to the nerves can also lead to long-term 
damage. 
 Tumors: Benign or malignant tumors of the nerves or nearby 
structures may damage the nerves directly, by invading the nerves, or cause 
neuropathy due to pressure on the nerves. 
 Idiopathic: Idiopathic neuropathy is neuropathy for which no cause 
has been established. The term idiopathic is used in medicine to denote the 
fact that no cause is known. 
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2.4.2 Pathogenesis of diabetic neuropathy: 
The cause of diabetic Neuropathy remains unknown but ischemic and   
metabolic complication are implicated. The following mechanisms seem to be 
involved:  
1. Increased flux through the polyol pathway, mediated by aldose 
reductase and sorbitol dehydrogenase, leading to accumulation of 
sorbitol and depletion of myo-inositol. The latter reduction is associated 
with reduced Na+-K+-ATPase activity41. 
 
Fig. No.3 Pathogenesis of diabetic neuropathy 
a. Endoneurial microvascular damage and hypoxia due to nitric oxide 
inactivation42.  
b. Accumulation of advanced glycation end products (AGEs) that exert 
their damaging effects by binding to specific receptors on the surface of 
neurons. Binding of AGEs to their receptors causes oxidative stress 
and activates nuclear factor-κB (NF-κB). There is increasing evidence 
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that the diverse agents able to activate NF-κB elevate levels of reactive 
oxygen species (ROS). Also, chemically distinct antioxidants and over 
expression of antioxidant enzymes can inhibit NF-κB activation41-44. 
c. Increased nerve lipid peroxidation in vivo. The most reliable index of 
increased oxidative stress is reduction in GSH42.  
d. Activation of protein kinase C (PKC) by increased release of 
intracellular diacylglycerol (DAG) due to glycolysis. Hyperglycemia 
activates PKC, especially its βII isoform through increased de novo 
synthesis of DAG. The increased activity of PKCβ may impair 
endoneurial blood flow. Recently, hyperglycemia has been associated 
with activation of PKC and increase in Na1.7 tetrodotoxin-sensitive 
voltage-gated sodium channel isoform; both of which play a critical role 
in the perception of pain45-48.  
e. Alterations in mitogen-activated protein kinases (MAPKs) result in a 
signaling cascade involved in the pathogenesis of peripheral diabetic 
neuropathy49.  
f. Abnormal Ca2+ homeostasis and signaling50. 
2.4.5 Diagnosis of diabetic neuropathy: 
Diagnose of neuropathy on the basis of symptoms and a physical 
exam51. The diagnosis of DN in time is very important because effective 
intervention will be possible only during the subclinical or early phase of 
dysfunction52. During the exam, check blood pressure, heart rate, muscle 
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strength, reflexes, and sensitivity to position changes, vibration, temperature, 
or light touch.  
Morphological testing: 
Measures such as sural nerve biopsies provide an opportunity to study 
the biochemical and morphometric parameters of myelinated and 
unmyelinated fiber populations using the light microscope. Analysis includes 
examination of the myelinated nerve fibre size and distribution, myelinated 
nerve fiber density, index of circularity, and a measure of focal fiber loss53 
Superficial Pain Testing: 
Pain sensation can be tested with a sterile safety pin. The site of 
testing varies with the specific algorithm but may include the dorsum of the 
great toe or the plantar aspect of the distal first, third and fifth toe of each foot. 
Most commonly, the stimulus is applied once per site. Results are scored 
accordingly54-55. 
Vibration perception thresholds: 
Vibration thresholds is performed using a handheld device (Bio- 
Thesiometer). This instrument quantitatively tests vibratory sensation with a 
specialized probr set at 100-1Hz and hasan adjustable amplitude ranging 
from 0-50 volts56. As an easy and traditional way to test vibratory sensation, 
the128Hz standard (non-graduated) tuning forkis a tool of screening for 
diabetic neuropathy. The risk of foot ulceration is increased 3-4 fold if the 
vibration perception threshold exceeds 25 volts. Vibrameter is also based on 
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the principle of biosthesiometer but results are given directly in mm of probe 
displacement52. 
Light touch sensation: 
Light touch perception can be evaluated by using a number of methods 
from a finger, to cotton, to specifically calibrated devices. The best known of 
the calibrated devices is the Semmes- Weinstein 10-g monofilament, a nylon 
filament embedded in a plastic handle57. A series of increasingly thick 
filaments are tested, and the threshold at which the first one can be felt when 
buckling is noted. The inability to feel the 10 gm filament indicate that patient 
is prone to foot ulceration52. 
Thermal thresholds: 
The Thermal threshold parameters studied were: (1) sensory 
thresholds to cold and heat and (2) pain thresholds induced by cold and heat 
on both palms and on the dorsum and soles of both feet50. The equipment 
used for thermal threshold assessment are expensive and mostly used for 
research purposes. Pain threshold can be determined either by application of 
high or low temperature or by using the “Pinchometer” or a series of weighted 
needles52. 
Electrophysiology: 
All electrophysiological studies were performed on a multiple channel 
EMG (Macro electromyography) apparatus56. Often performed along with 
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nerve conduction studies, electromyography measures the electrical 
discharges produced in the muscles. 
Nerve conduction studies. These measure the ability of peripheral 
nerves to conduct electrical impulses and are abnormal when pathological 
changes are present in myelinated nodes of Ranvier and axons51.  
Autonomic testing  
Symptoms of autonomic neuropathy, may request special tests to look 
the blood pressure in different positions and assess the ability to sweat51. 
A check of heart rate variability 
It shows how the heart responds to deep breathing and to changes in 
blood pressure and posture.  
Ultrasound: 
It uses sound waves to produce an image of internal organs. An 
ultrasound of the bladder and other parts of the urinary tract, for example, can 
be used to assess the structure of these organs and show whether the 
bladder empties completely after urination. 
Foot Exams:  
Experts recommend that people with diabetes have a comprehensive 
foot exam each year to check for peripheral neuropathy. People diagnosed 
with peripheral neuropathy need more frequent foot exams51. 
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2.5 PAIN: 
Pain has been defined as “an unpleasant sensory or emotional 
experience associated with actual or potential tissue damage”60. 
Classification of pain61:  
 
Fig. No. 4 Classification of pain 
2.5.1 NOCICEPTOR: 
A nociceptor is a type of receptor at the end of a sensory 
neuron's axon that responds to damaging or potentially damaging stimuli by 
sending pain signals to the spinal cord and the brain. This process is 
called nociception62. 
The peripheral terminal of the mature nociceptor is where the noxious 
stimuli are detected and transduced into electrical energy. When the electrical 
energy reaches a threshold value, an action potential is induced and driven 
towards the central nervous system (CNS). The sensory specificity of 
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nociceptors is established by the high threshold only to particular features of 
stimuli. Only when the high threshold has been reached by either chemical, 
thermal, or mechanical environments are the nociceptors triggered. The 
majority of nociceptors are classified by which of the environmental modalities 
they respond to. Some nociceptors respond to more than one of these 
modalities and are consequently designated polymodal. Other nociceptors 
respond to none of these modalities (although they may respond to 
stimulation under conditions of inflammation) and are referred to as sleeping 
or silent63.  
Nociceptors have two different types of axons. The first are the Aδ 
fiber axons. They are myelinated and can allow an action potential to travel at 
a rate of about 20 meters/second towards the CNS. The other type is the 
more slowly conducting C fiber axons. These only conduct at speeds of 
around 2 meters/second. This is due to the light or non-myelination of the 
axon. As a result, pain comes in two phases. The first phase is mediated by 
the fast-conducting Aδ fibers and the second part due to (Polymodal) C fibers. 
The pain associated with the Aδ fibers can be associated to an initial 
extremely sharp pain. The second phase is a more prolonged and slightly less 
intense feeling of pain as a result of the acute damage. If there is massive or 
prolonged input to a C fiber, there is a progressive build up in the spinal cord 
dorsal horn; this phenomenon is similar to tetanus in muscles but is 
called wind-up. If wind-up occurs there is a probability of increased sensitivity 
to pain64-65.  
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Inflammatory mediators (e g bradykinin, serotonin, prostaglandins, cytokines, 
and H+) are released from damaged tissue and can stimulate nociceptors 
directly. They can also act to reduce the activation threshold of nociceptors so 
that the stimulation required to cause activation is less. This process is called 
primary sensitisation66. 
2.6 NEUROPATHIC PAIN: 
Neuropathic pain is pain caused by damage or disease affecting 
the somatosensory nervous system. Neuropathic pain may be associated with 
abnormal sensations called dysesthesia or pain from normally non-painful 
stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) 
components. The latter resemble stabbings or electric shocks. Common 
qualities include burning or coldness, "pins and needles" sensations, 
numbness and itching67.  
2.7 PAIN PROCESS: 
There are four steps involved in how our bodies process pain11. 
 Transduction 
 Transmission 
 Perception 
 Modulation 
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Transduction: 
Transduction is the conversion of a noxious stimulus (mechanical, 
chemical or thermal) into electrical energy by a peripheral nociceptor (free 
afferent nerve ending)11.            
This process begins when peripheral nerve terminals of nociceptor C 
fibres and A-delta (Aδ) fibres are depolarised by noxious mechanical, thermal 
or chemical energy. The membranes of these terminal contains protein and 
voltage-gated ion channels that convert thermal, mechanical or chemical 
energy into action potencial (AP). Nociceptor terminals spread densely 
throughout the skin68. Nociceptors are exposed to noxious stimuli when tissue 
damage and inflammation occurs as a result of, for example trauma, surgery, 
inflammation, infection, and ischemia. 
The nociceptors are distributed in the: 
 Somatic structures (skin, muscle, connective tissue, bones, joints) 
 Visceral structures (Visceral organs such as liver, gastro-intestinal 
tract) 
 The C fibre and A-delta fibres are associated with different qualities of 
pain. 
The chemical mediators like Prostaglandin, bradykinin, serotonin, 
suptance P, Potassium, Histamine are activate and / or sensities the 
nociceptor to the noxious stimuli. In order for a pain impulse to be generated  
an exchange of sodium and potassium ions (depolorisation and re-
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polarisation) occurs at the cell membranes. This results in an action potential 
and generation of a pain impulse68. 
 
Fig. No. 5 Pain Process 
2.7.2 TRANSMISSION: 
The transmission process in three stage. The pain impulse is 
transmitted: 
1. From the site of transduction along the nociceptor fibres to the 
dorsal horn in the spinal cord. 
2. From the spinal cord to the brain stem. 
3. Through connections between the thalamus, cortex and higher 
levels of the brain. 
The C fibre A-delta fibres terminate in the dorsal horn of the spinal cord. 
There is a synaptic cleft between the terminal ends of the C fibre and A-delta 
fibres and the nociceptive dorsal horn neurons (NDHN). In order for the pain 
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impulses to be transmitted across the synaptic cleft to the NDHN. Excitatory 
neurotransmitters are released, which bind to specific receptors in the NDHN. 
These neurotransmitters are: 
 Adenosine triphosphate 
 Glutamate 
 Calcitonin gene-related peptide 
 Bradykinin 
 Nitric oxide 
 Substance P  
The pain impulse is then transmitted from the spinal cord to the brain 
stem and thalamus via two main nociceptive ascending pathways. These are 
the spinothalamic pathway and the spinoparabrachial pathway. 
The brain does not have a discrete pain centre, so when impulses 
arrive in the thalamus they are directed to multiple areas in the brain where 
they are prosessed68.  
2.7.3 MODULATION: 
Modulation of nociceptive transmission is an adaptive process involving 
both excitory and inhibitory mechanisms. Peripheral modulation can be 
accomplished by69: 
 Inhibiting the sensitization of nociceptor terminals  
 Inhibiting depolarization and repolarization of the axonal membrane by 
preventing the generation or conduction of an action potential by 
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blocking the influx of sodium through voltagegated sodium channels 
located along first and second order afferents. 
 Inhibiting the inflammatory responses to trauma with hydrocortisone. 
 Stimulating the large fast Aβ fibers in the area of injury can induce 
interneurons in the dorsal horn to release GABA and glycine which 
inhibit the release of glutamate from the primary afferent terminal, there 
by preventing depolarization of the second order neuron. Mechanical 
stimulation and transcutaneous electrical nerve stimulation (TENS) are 
believed to reduce the perception of pain by activating fast Aβ fibersR. 
2.7.4 PERCEPTION: 
Perception of nociceptive pain is dependant upon neural processing in 
the spinal cord and several brain regions. Pain becomes more than a pattern 
of nociceptive action potentials when they reach the brain. Action potentials 
ascending the spinothalamic tract are decoded by the thalamus, sensorimotor 
cortex, insular cortex and the anterior cingulate to be perceived as an 
unpleasant sensation that can be localized to a specific region of the body. 
Action potential ascending the spinobulbar tract are decoded by the amygdala 
and hypothalamus to generate a sense of urgency and intensity. It is the 
intergration of sensations, emotions and cognition that result in our perception 
of pain69. 
2.8 PAIN PATHWAY: 
          There are two pain pathways they are ascending pathway and 
descending pain pathway. 
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2.8.1 Ascending Pathway:  
          The central processes of the afferent neurons enter the brain or spinal 
cord and synapse upon interneurons there. The central processes diverge to 
terminate on several, or many, interneurons and converge so that the 
processes of many afferent neurons terminate upon a single interneuron. The 
interneurons upon which the afferent neurons synapse are termed second-
order neurons, and these in turn synapse with third-order neurons, and so on, 
until the information (coded action potentials) reaches the cerebral cortex70. 
Various sensory signals take two different paths to reach the brain, 
both of which start in a given part of the body and end in the brain’s 
somatosensory cortex15. Each of these paths consists of a chain of three 
neurons that pass the nerve impulses from one to the next. Where these two 
paths differ is in the location where they cross the midline in the spinal cord. 
The nerves responsible for sensory inputs, as well as those responsible for 
motor control, are crossed. In other words, the neural pathways from the left 
side of the body terminate in the right hemisphere of the brain, and vice versa. 
Hence, at some point in the body, these pathways must cross the body’s 
midline (in scientific terminology, they must “decussate”). 
Any incoming sensory impulse-whether for touch, pain, heat, or 
proprioception-follows from the spinal cord to the brain. Regardless of the 
sensory modality, the three neurons in the form of  a chain running from one 
side of the spinal cord to the other, and the cell body of the first neuron in this 
chain is always located in a spinal (dorsal root) ganglion. This neuron is said 
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to be T-shaped, because its axon emerges as a short extension from its cell 
body and then soon divides into two branches going in opposite directions: 
one goes to the part of the body that is innervated by this spinal nerve, while 
the other immediately enters the dorsal root of the spinal cord (an essentially 
sensory part of the spinal cord, as opposed to the ventral root, which is a 
motor area). It is from this point on that the two pathways differ. 
 The pathway responsible for touch and proprioception is called the 
Lemniscal pathway. The first axon in this pathway runs along the dorsal root 
of the spinal nerve and up the dorsal column of the spinal cord. (Along the 
way, this axon also sends out collaterals: branches in the dorsal root that play 
a valuable role in the local inhibition of pain, among other functions.)  
The primary axon, however, remains on the same side of the spinal 
cord as the side of the body that it innervates (the “ipsilateral” side) until it 
connects with the second neuron in the chain, which in the case of the 
lemniscal pathway is located in the medulla. The axon of this second neuron 
crosses the midline immediately. It then travels up through the medial 
lemniscus to the ventral poster lateral (VPL) nucleus of the thalamus, where it 
connects with the third neuron in the chain.  
The pathway that carries information about pain and non-painful 
temperatures is called the neo spinothalamic pathway (or often simply the 
spinothalamic pathway). The first neuron in this pathway connects to the 
second neuron not in the medulla, but in the dorsal horn of the spinal cord, on 
the same side that the nerve impulse comes from. This second neuron has a 
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single axon, which immediately crosses the midline to the other (contralateral) 
side of the spinal cord and goes up to the brain along with the other axons 
forming the lateral spinothalamic tract. This part of the pathway is described 
as contralateral, meaning that it runs along the side of the body opposite to 
the area that its axons innervate. 
The axon of the second neuron connects to the third and final neuron 
of this ascending pathway in the ventral posterolateral (VPL) nucleus of the 
thalamus. In both of these pathways, the third neuron sends its axon to the 
somatosensory cortex, the part of the brain that determines exactly where the 
original stimulus occurred in the body71. 
 
 
Fig. No. 6 Pain Processing Pathways  
2.8.2 DESCENDING PATHWAYS: 
            A nerve pathway that go down the spinal cord and allow the brain to 
control movement of the body below the head. Descending pathways begin in 
the periaqueductal gray (PAG).Stimulation of the PAG has been shown to 
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produce analgesia, but no change in the ability to detect temperature, 
pressure, or touch. The neurons beginning in the PAG end on cells in the 
medulla, including the serotonergic cell bodies of the raphe nuclei. The 
serotonergic neurons then descend into the spinal cord to inhibit cell firing. 
Other cells in the PAG terminate close to the locuscoeruleus in the brainstem. 
Thus, there are at least two major pathways that descend to the spinal cord to 
inhibit the projection of pain72.    
2.9 TREATMENT OF DIABETIC NEUROPATHY: 
The treatment of diabetic neuropathy can be broadly divided into two 
major groups51,73-75 
1. Symptomatic treatment. 
2. Treatment for nerve regeneration.  
Symptomatic Treatment: 
Pain is the most common symptoms which could be superficial, deep 
or aching. Simple reassurance that the pain is not permanent, does produce 
great relief from pain, pain related anxiety or depression. However, following 
measures can be take in order of preference for pain relief:   
1. Tricyclic anti-depressants: 
 Imipramine 
 Amitriptyline 
 Desipramine 
 Nortriptyline 
 Clomipramine 
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2.Anti-convulsants: 
 Carbamazepine 
 Clonazepam 
 Phenytoin 
 Gabapentin 
 Pregabalin 
3.Serotonin- Norepinephrine reuptake inhibitors: 
 Duloxetine 
 Venlafaxine 
4.Selective serotonin reuptake inhibitors: 
 Fluoxetine 
 Paroxetine 
 Sertraline 
 Citalopram 
5.Antioxidants: 
 Alpha-lipoic acid 
6.Opioids: 
a. Typical opioid: 
 Oxycodone 
b.Atypical opioids: 
 Tramadol 
 Tapentadol 
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Topical agents: 
Treatments that are applied to the skin typically to the feet. sprays or 
patches for the feet may relieve pain. Oil are suggest they may help relieve 
symptoms and improve nerve function in some patients. 
 Capsaicin 
 Clonidine 
 Lidocaine patch 
 Nitrate sprays or patches 
 Primrose oil 
Miscellaneous: 
 Bed cradle can keep sheets and blankets from touching sensitive feet 
and legs.  
 Acupuncture 
 Biofeedback or physical therapy() 
 Electrical nerve stimulation  
 Magnetic therapy 
 Laser or light therapy 
 Hot wax 
 Monochromatic infrared photo energy(MIRE) 
 Interferential current(IFC) 
 Therapeutic ultrasound 
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Treatment for nerve regeneration: 
The pathologic basis for the treatment of diabetic neuropathy, it is 
important to enhance nerve regeneration as well as prevent nerve 
degeneration76. Nerve regeneration or sprouting in diabetes may occur not 
only in the nerve trunk but also in the dermis and around dorsal root ganglion 
neurons, thereby being implicated in the generation of pain sensation. Nerve 
regenerative capacity has been shown to be decreased in diabetic patients as 
well as in diabetic animals. Rationally accepted replacement therapy with 
neurotrophic factors has not provided any success in treating diabetic 
neuropathy. Aside from adverse effects of those factors, more rigorous 
consideration for their delivery system may be needed for any possible 
success. Although conventional therapeutic drugs like aldose reductase (AR) 
inhibitors and vasodilators have been shown to enhance nerve regeneration, 
their efficacy should be strictly evaluated with respect to nerve regenerative 
capacity.  
2.10 TREATMENT DESIGNED TO MODIFY THE COURSE OF DIABETES: 
  The treatment of diabetic neuropathy is aimed at preventing the 
progression of neuropathy and providing symptomatic relief. 
Glycaemia control: 
Regulation and maintenance blood glucose levels within normal 
ranges; aim of the treatment of diabetes mellitus (by diet, oral hypoglycaemic 
agents or parenteral insulin), longterm glycaemic control reduces later 
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incidence of secondary diabetic complications77.  Tight glycemic control is the 
only strategy convincingly shown to prevent or delay the development of 
neuropathy in patients with type 1 diabetes and to slow the progression of 
neuropathy in some patients with type 2 diabetes78. Studies have shown that 
good control can prevent or delay the onset of diabetic peripheral neuropathy. 
The effectiveness of normoglycaemia in improving damaged nerves has been 
documented in some patients who have undergone combined pancreatic and 
renal transplantation79. 
Aldose reductase inhibitors: 
Aldose reductase is an enzyme that is normally present in many other 
parts of the body, and catalyzes one of the steps in the sorbitol(polyol) 
pathway that is responsible for fructose formation from glucose. Aldose 
reductase activity increases as the glucose concentration rises in diabetes in 
those tissues that are not insulin sensitive, which include the lenses, 
peripheral nerves and glomerulus. Sorbitol does not diffuse through cell 
membranes easily and therefore accumulates, causing osmotic damage 
which leads to retinopathy and neuropathy. The aldose reductase inhibitors 
prevent conversion of glucose to sorbitol in presence of hyperglycaemia, 
Therefore, it prevents the polyol pathway cascade. ARIs are alreastat, 
tolerestat, epalrestat, sorbinil, and zopolrestat. There is great controversy 
about the mechanisms of action of the ARIs, and suggestions range from 
altered phosphoinositide metabolism and Na+ - K+ adenosine triphosphate 
activity, through reduced glutathione levels, to vasodilation and improved 
blood flow to nerve80-81. 
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Alpha-Lipoic acid: 
The antioxidant alpha-lipoic acid (or ALA), taken in pill form, lessened 
pain in people with diabetic neuropathy or nerve damage resulting from 
diabetes. ALA is a sulfur-containing compound that is made in small amounts 
in the body but is not found in food82-83. It’s potent antioxidant, prevents or 
improves nerve conduction attributes, endoneurial blood flow, and nerve 
Na+ K+ ATPase activity in experimental diabetes and in humans and may 
improve positive neuropathic sensory symptoms. 
Carnitine: 
Acetyl-L-carnitine (ALC) is deficient in diabetes83. Acetyl-L-carnitine 
(ALC), a constructive molecule in fatty acid metabolism, is an agent potentially 
effective for treating neuropathic pain (NP). It is also called as nerve productor 
or nervepredicting agent Acetyl L-Carnitine which involved in the energy 
production of human body. Carnitine made in liver and kidneys from the 
aminoacids. Acetyl L-Carnitine improves the cells ability to produce energy, 
this allows the cells to do their jobs. But more energy creates more free-
radicals. Adding Alpha Lipoic Acid to the Aceytl L-Carnitine handles these free 
radicals. The cell producing better, can now use cholesterol and B vitamins to 
repair the nerve cells. 
2.11 DIABETES INDUCING AGENTS: 
At present time best and quickest way to induce diabetes is with use of 
chemicals (alloxan, streptozotocin, dithizone, monosodium glutamates etc.), 
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viruses and genetically diabetic rats. In recent years, scientists and 
technologists have worked toward refining techniques that have led to the 
discovery of chemical agents that physiologically alter the function of the 
pancreas. The main advantage of using such chemicals is that body changes 
during and after the induction of diabetes can be observed. The five major 
diabetogenic agents are chemicals, biological agents, peptides, potentiators, 
and steroids but most commonly used chemical agents are alloxon and 
streptozotozine84 
Alloxan:  
  Alloxan (2, 4, 5, 6-tetra oxy pyrimidine; 2, 4, 5, 6- pyrimidinetetrone) is 
an oxygenated pyrimidine derivative which is present as alloxan hydrate in 
aqueous solution. It is most prominent chemical compound used in 
diabetogenic research. In research it is used for induction of Type 1 diabetes. 
Alloxan is a urea derivative which causes selective necrosis of the β- cells of 
pancreatic islets It has been widely used to induce experimental diabetes in 
animals such as rabbits, rats, mice and dogs with different grates severity by 
varying the dose of alloxan used85-86.  
Mechanism action of Alloxan: 
Alloxan are toxic glucose analogues that preferentially accumulate in 
pancreatic beta cells via the GLUT2 glucose transporter. In the presence of 
intracellular thiols, especially glutathione, alloxan generates reactive oxygen 
species (ROS) in a cyclic redox reaction with its reduction product, dialuric 
acid. Autoxidation of dialuric acid generates superoxide radicals, hydrogen 
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peroxide and, in a final iron-catalysed reaction step, hydroxyl radicals. These 
hydroxyl radicals are ultimately responsible for the death of the beta cells, 
which have a particularly low antioxidative defence capacity, and the ensuing 
state of insulin-dependent 'alloxan diabetes'. As a thiol reagent, alloxan also 
selectively inhibits glucose-induced insulin secretion through its ability to 
inhibit the beta cell glucose sensor glucokinase. 
Streptozotocin:  
  Streptozotocin is naturally occurring chemical; used to produce Type- 1 
diabetes in animal model and Type- 2 diabetes with multiple low doses. It is 
also used in medicine for treating metastatic cancer of islets of Langerhans87. 
Streptozotocin was originally identified in the late 1950s as an 
antibiotic. The drug was discovered in a strain of the soil microbe 
Streptomyces achromogenes. The soil sample in which the microbe turned up 
had been taken from Blue Rapids, Kansas, which can therefore be considered 
the birthplace of streptozotocin. 
 
Fig. No.8 2-deoxy-2-{[methyl (nitroso) amino] carbonyl} amino)--D-glucopyranose 
  
Dept. of Pharmacology, The Erode College of Pharmacy & Research Institute  40 
MECHANISAM OF STREPTOZOTOCIN: 
STZ is a broad-spectrum antibiotic that is toxic to the insulin 
producing β cells of pancreatic islets. It is currently used clinically for the 
treatment of metastatic islet cell carcinoma of the pancreas and has been 
used investigationally in a wide variety of large and small animal species. The 
method of STZ action in β cell depletion has been studied extensively over the 
years. Streptozotocin prevents DNA (Deoxyribonucleic acid) synthesis in 
mammalian and bacterial cells, in the bacterial cells; it renders special 
reaction with cytosine groups, resulting in degeneration and destruction of 
DNA. The streptozotocin enters the pancreatic cell via a glucose transporter-
GLUT2 (Glucose transporter 2) and causes alkylation of DNA. Further STZ 
induces activation of poly adenosine diphoshate ribosylation and nitric oxide 
release, as a result of STZ action, pancreatic -cells are destroyed by necrosis 
and finally induced insulin dependent diabetes88-89.   
Dithizone: 
Dithizone induced the symptoms of diabetes in cats, rabbits, golden 
hamsters and in mice. In dithizonised diabetic animals, the levels of serum 
zinc, iron, and potassium were found to be higher than normal but copper and 
magnesium levels were unchanged. After treatment with insulin, most of these 
serum levels were normal, except for serum potassium and magnesium90.   
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Mehanism of Dithizone: 
 Zinc-chelating agent such as dithizone is causes diabetes in laboratory 
animals. Dithizone has abilities to permeate membranes and to complex zinc 
inside liposomes with the release of protons, that can enhance 
diabetogenicity. When such complexing agents are added to lipid vesicles at 
pH 6 containing entrapped zinc ions, they acidify the contents of these 
vesicles. Such proton release occurs within the zinc-containing insulin storage 
granules of pancreatic beta-cells; solubilisation of insulin would be induced 
which leads to osmotic stress and eventually the granule rupture and finally 
diabetes is induced91.   
Gold thioglucose: 
  Gold thioglucose is diabetogenic compound, which is induced 
hyperphagia and severe obesity induced Type -2 diabetes.  
Mechanism of Action Gold thioglucose: 
 Developed obesity induces diabetes in genetically normal mouse 
strains. Gold thioglucose treated DBA/2 (Dilute Brown Non- Agouti), 
C57BLKs, and BDF1 mice gained weight rapidly and significantly increase 
non fasting plasma glucose level within 812 weeks. These mice showed 
impaired insulin secretion, mainly in early phase after glucose load and 
reduced insulin content in pancreatic islets92.   
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Monosodium glutamate: 
 Monosodium glutamate induces Type -2 diabetes without polyphagia.  
Mechanism of Action: 
 Monosodium glutamate causes a very large insulin response after 
ingestion. It is developed glycosuria in both male and female mice but not 
induced polyphagia. Within 29 weeks level of glucose concentration in blood, 
total cholesterol and triglyceride were higher93.   
Other diabetogenic agents: 
1. Dehydroascorbic acid 650/kg for three days in rat 
2. Dehydroascorbic acid 1.5 mg/kg in rat 
3. Dehydroglucoascarbic acid 3.5-3.9 gm/kg in rat 
4. Methyl alloxan 53mg/kg in rat 
5. Ethyl alloxan 53-130 mg/kg in rat 
6. Oxime and dithizone 53 mg/kg in rabbit  
7. Sodium diethyldithiocarbonate 0.5-1 gm/kg in rabbit 
8. Pottasium xanthate 200-350 mg/kg in rabbit 
9. Uric acid 1 gm/kg in rabbit 
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2.12 PREGABALINE: 
 
 
 
Fig. No. 9 Pregabalin,(S)-3-(aminomethyl)-5-methylhexanoic acid, 
is a pharmacologically active S-enantiomer of a racemic 3- isobutyl gamma 
amino butyric acid analogue. It is a well-established anticonvulsant and 
analgesic agent. In fact Pregabalin is the first drug to receive an approved 
labelling from Food and Drug Association (FDA) for the treatment of diabetic 
neuropathy and post herpatic neuralgeia. The major advantage of pregabalin 
is its relative reliability, easy use and high tolerance in patients with 
neuropathic pain. Pregabalin is structurally related to the antiepileptic drug 
gabapentin and the site of action of both drugs is similar, the alpha2-delta 
(alpha2-delta) protein, an auxiliary subunit of voltage gated calcium channels. 
Pregabalin, marketed under the brand name Lyrica among others, is a 
medication used to treat epilepsy, neuropathic pain, fibromyalgia, and 
generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for 
partial seizures with or without secondary generalization in adults. Some off 
Label uses of pregabalin include restless leg syndrome, prevention of 
migraines, social anxiety disorder, and alcohol withdrawal. When used before 
surgery it does not appear to affect pain after surgery but may decrease the 
use of opioids. 
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MECHANISM OF PREGABALIN: 
Pregabalin blocks the VGCC and hence decrease glutamate and 
sensory neuropeptides (substance P and CGRP) release at synapse by 
decreasing Ca2+ influx. EAATs (excitatory amino acid transporters) activity is 
increased by pregabalin which caused more decrease in synaptic availability 
of glutamate. Decreased glutamate levels further inhibited the activation of 
NMDA and decreased the neuronal firing. Additionally pregabalin also 
activates the KATP channels, which also contributes to inhibition of neuronal 
excitation. Pregabalin through all these pathways ultimately provides 
significant pain relief in various neuropathic pain states94. 
LITERATURE REVIEW OF DIABETIC NEUROPATHY: 
95. Faisal Mohd et al., reported “The Pharmacological Evaluation of 
Epigallocatechin-3-Gallate (EGCG) Against Diabetic Neuropathy in Wistar 
rats”. The observation of this indicates that hyperglycemia and oxidative 
stress is responsible for the development of diabetic neuropathy. Protective 
effect of EGCG against diabetic neuropathy could be due to controlling 
hyperglycemia and reducing oxidative stress. This could provide a rational for 
the use of Epigallocatechin-3-gallate in fever folk medicine. 
96. “Evaluation of Neuroprotective Effect of Ficus benghalensis against 
alloxan induced diabetic neuropathy in rats”. This study has revealed that oral 
administration of Methanolic extract of Ficusbenghalensis leaves not only 
attenuated the alloxan induced diabetic condition but also reversed the 
neuropathic pain. The probable mechanism could be via enhancing insulin 
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production and decreasing the glucagon production. The onset of neuropathic 
complications could be prevented by early gly cemiccontrol and it was 
reported by Stalin et al., 
97. Alsharari et al., revealed the “Ameliorative potential of morin in 
streptozotocin induced neuropathic pain in rats”. The present study is 
aboutmorin ameliorative hyperglycemia induced mechanical or thermal 
hyperalgesia and lowers neuropathic pain by reducing oxidative stress in the 
nerve of diabetic rats by virtue of its antioxidative and antiinflammatory 
properties. Morphological assessments show that the sciatic nerve is also 
markedly reduced by the administration of morin. These findings suggest that 
morintraetment might be beneficial in chronic diabetics exhibiting neuropathy. 
98. “Effects of Ethyl Acetate Fraction of Ziziphus mauritianaLam. 
Leaves on STZ induced diabetes and diabetic neuropathy in mice”. The study 
indicates that STZ induced diabetic mice shows elevated blood glucose level 
and reduced pain threshold in thermal hyperalgesia and cold allodynia, and 
also reduced motorinco-cordination. Ethyl Aceteate fraction of Methanolic 
extract of Ziziphusmaurititana Lam. leaves has Antidiabetic activity and also 
protective against diabetic neuropathy in STZ induced diabetic mice was 
studied by Mohammed Mubashir et al., 
99. Amit Kumar Gangwar et al., reported “Investigation of 
Neuroprotective Effect of Rasagiline in diabetic neuropathy in Streptozotocin 
induced Type-2 diabetic rats”.This study indicates Rasagline combine with 
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glimiperide significant reduce in symptoms of diabetic neuropathy in a dose 
dependent amnner. 
100. Parkar N &Addepalli V et al., studiedNobiletin on Diabetic 
Neuropathy in Experimental rats. This study concluded t hat treatment with 
nobiletin ameliorated diabetic neuropathy in STZ rats which was evident by 
improved nociceptive latency and nerve conduction velocity. Thus the results 
of the study lead to suggest the protective role of nobiletin in STZ induced 
diabetic neuropathy. 
101. Neuroprotective effects of Gymnema sylvestreonstreptozotocin-
induced diabetic neuropathy in rats. The present study demonstrate the 
ameliorative properties of GSextract against chemically-induced DN in rats via 
its antihyperglycemic, antioxidative and anti-inflammatory properties. 
Furthermore, morphological examinations indicate that the damage caused to 
the sciatic nerve by STZ was markedly reduced following the administration of 
GS. Therefore, GS extract application may be useful for the treatment of 
neuropathy in patients with chronic diabetes was revealed by Amal Jamil 
Fatani et al., 
102. “Effect Of CocciniaIndica Leaf Extract On Diabetic Neuropathy 
Pain In Rats”. This study indicates that freshly prepared Coccinia indica 
attenuates hyperglycemia and diabetic neuropathy in STZ-induced diabetic 
rat, due to antihyperglycemic and analgesic activity. We also showed that 
higher dose of Coccinia indica plant extracts (500 mg/kg/day) have more 
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blood glucose lowering effects when treatment started one week after the STZ 
injection, It was proved by Ravikant  et al., 
103. Sandeeep Kumar K et al., Experimentally studied the 
“Neuroprotective effect of ethanolic root extract of Boerhaavia diffusa (Linn.) 
against Streptozotocin induced Diabetic neuropathy in animal model”. The 
present study has shown that, the ethanol extract of B. diffusa root have 
attenuated the STZ induced diabetic neuropathy in rats. These effects may be 
attributed to its potential antidiabetic, anti-oxidant and calcium channel 
blocking properties. 
104. Pratibha D Nadig et al., reported “Effect of Tinospora cordifolia on 
experimental diabetic neuropathy”. The invitro effect of TC on aldose 
reductase inhibition was observed. It showed an inhibitory effect although the 
IC50 was higher as compared to the standard (quercetin). Thus, the beneficial 
effect of TC on diabetic neuropathy appears to be due to its analgesic effect 
and unrelated to its antihyperglycemic effect. Aldose reductase inhibition may 
contribute to this action. An antioxidant role of TC cannot be ruled out as 
oxidative damage contributes to the causation of diabetic neuropathy and TC 
is proven to be an antioxidant in experimental models.  
105.  Ravichandran Ranjithkumar et al., “Standardized Aqueous 
Tribulus terristris (Nerunjil) extract attenuates hyperalgesia in experimentally 
induced diabetic neuropathic pain model: Role of oxidative stress and 
inflammatory mediators” this study confessed that nerunjil attenuated the 
neuropathic pain through modulation of oxidative stress and inflammatory 
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cytokine release in diabetic states. These findings suggest that neunjil may 
potentially have clinical applications to treat neuropathic pain in diabetic 
animals. 
106. Ramdas B. PandhareI, et al., revealed that “Attenuating effect of 
seeds of Adenanthera pavonina aqueous extract in neuropathic pain in 
streptozotocin-induced diabetic rats: an evidence of neuroprotective effects”. 
pregabalin is well documented to exert its beneficial effect in neuropathic pain 
via  inhibition of voltage gated calcium [Cav 2.2 (a2­δ subunit)] channels and 
therefore, it  is proposed that potential anti-oxidative and neuroprotective 
actions of Adenanthera pavonina may be an important factor in attenuating 
STZ-induced diabetic peripheral neuropathic pain. 
107. Gowhar Ali et al., revealed that “A streptozotocin induced diabetic 
neuropathic pain model for static or dynamic mechanical allodynia and 
vulvodynia: validation using topical and systemic gabapentin”. This study 
confessed that outcomes of topical and systemic gabapentin in the diabetic 
neuropathy model of vulvodynia tend to validate it as a useful non-clinical 
paradigm. The complex nature of the diabetic neuropathic pain syndrome and 
the unpredictable rate of absorption of gabapentin from the gel formulation 
warrent further research to correlate any antivulvodynia activity of gabapentin 
gel with gabapentin penetration after topical appilcation. 
108. “Neuroprotective effect of Cerebrolysin on Diabetic neuropathy: A 
study on male rats” by Naseer Zangiabadi et al., In the present study it was 
observed that intraperitonial injection of cerebrolysin is effective in the 
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treatment of diabetic neuropathy and can improve the function of peripheral 
nerves. 
109. Jurairat Khongrum et al., reported “Moringa Oleifera leaves 
extract attenuates neuropathic pain induced by chronic constriction injury”. 
The possible mechanism underlying these studies may be M.oleifera exert the 
antioxidant effect. However, these, the precise underlying mechanism still 
require further investigation. 
110. Saeed Esmaeili-Mahani et al., “Olive (Oleaeuropaea L.)Leaf 
extract attenuates early diabetic neuropathic pain through prevention of high 
glucose-induced apoptosis: In vitro and in vivo studies”. The study suggest 
that olive leaf extract rescues PC12 cells against high glucose-induced neural 
damage and attenuates thermal hyperalgesia in diabetic rats. The 
mechanisms of these effects may be due, at least in part, to reduce neuronal 
apoptosis.  Therefore, the data suggest therapeutic potential of o live leaf 
extract in attenuation of diabetic neuropathic pain. 
111. Roman adhikari, jyothi yet al., “Combined effect of aqueous 
extract of curcuma longa Linn With metformin in diabetes induced neuroptahic 
pain in rats “This study reveals Uncontrolled blood glucose level leading to 
hypoglycemia, oxidative stress, and end-organ complications can ultimately 
become fatal. A number of commercially available OHAs though are effective 
in controlling the blood glucose, long-term use of the higher doses reports 
severe side effects. Hence, herbal drugs possessing anti-diabetic and anti-
oxidant properties are desired for long-term treatment in order to reduce the 
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dose of commonly used OHA and avoid their side effects. The basic 
pathophysiology of diabetes involves the destruction of β-cell or its improper 
functioning in secreting insulin due to unwanted metabolic changes, hence β 
cells become more compromised to the stimuli that demands excess insulin 
for the body. CUR has a property of protecting the islets β-cell, decrease the 
insulin resistance and decrease the oxidative stress. Hence, the use of CUR 
along with the OHA could be useful in preventing the complications 
associated with Diabetes when subjected to prolonged treatment.   
112. N Premkumar et al., reported Antinociceptive property of Emblica 
Officinalis garten in high fat diet fed/low dose Streptozotocin induced diabetic 
neuropathy in rats. This study reveals that E.officinalis fruit extract induced 
reduction in oxidative stress secondary to decrease in blood glucose level 
may be responsible for ameliorting axonal degenration and neuropathy in 
sciatic nerve EOE has produced a pronounced antinociceptive activity from 
3week onwards but not quercetin and thus it can prevent as well as cure 
diabetic neuropathy. The curative and preventive property of EOE in diabetic 
neuropathy may be due to its improvement in glucose in tolereance and 
antioxidant property.     
113. Archana jorige et al., “Neuroprodective and antioxidant role of 
pregabalin in sterptozotocine induced neurotoxicity” the present study 
revealed that 15mg/kg pregabalin significantly prevented the amelioration of 
defensive antioxidant enzyme levels and reduced the lipid peroxidation in 
sciatic nerves of STZ induced diabetic rat model. It also prevented the 
abnormal structural changes of sciatic nerve in diabetic rats. There by the 
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present study uncovered the neuroprotective action of pregabalin in STZ 
induced neurotoxicity. The anti-neuropathic effect of pregabailn was not only 
mediated through its action on voltage gated Ca+2 but also through its 
antioxidant action by the restoration of endogenous antioxidant enzyme 
levels. 
114. Sameer Nasikkar et al., “Protective effect of Lagerstroemia 
speciosa leaves extract against streptozotocin induced diabetic neuropathy in 
experimental rats”. The present data conclude that the repeated dose 
treatment of Lagerstroemia Speciosa leaves extract for four weeks in diabetic 
rats not only attenuate the hyperglycemic condition but also reversed DPN 
symptoms. It is a potent anti-diabetic and antioxidant, which has observed as 
its ameliorative effects.   
115. Solanki nilay D et al., “Experimental study on operculina 
turpethum in STZ induced diabetic neuropathy, neurodegeneration and 
cardiovascular complications”. These studies have concluded that there is 
definite role of operculina turpethum in the reversal of major diabetic 
complications especially neuropathy and cardiovascular complication. In this 
study number of animals utilized was limited as per ethical apporuval, so 
further extrapolation of this study need to he done by using other species of 
animals. 
116.Nasser Zangiabadi et al., “The Effect of Angipars on Diabetic 
Neuropathy in STZ Induced Diabetic Male Rats”. In this study on Behavioural, 
Electrophysiological, Sciatic Histological and Ultra structural Indices. 
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According to the obtained results in the present study and the results of 
previous studies injection of Anipars for two weeks, in spite of not being 
effective on some indices, has some positive effects on the treatment and 
decrease of physiologic symptoms of neuropathy in male rats. Moreover it 
should be mentioned that Angipars at dose of 10ml/kg has the most positive 
effects on some indices of diabetic neuropathy. 
117. Seigo Usuki et al., “Effect of pre-germinated brown rice intake on 
diabetic neuropathy in Streptozotocin induced diabetic rats”. Pre-germinated 
Brown Rice or White rice treatment shows efficacy for protecting diabetic 
deterioration and for improving physiological parameters of diabetic 
neuropathy in rats, as compared with a brown rice or white rice diet. This 
effect may be induced by a mechanism whereby Pre-germinated brown rice 
intake mitigates diabetic neuropathy by one or more factors in the total lipid 
fraction. The active lipid fraction is able to protect t he Na+/K+/ATP ase of the 
sciatic-nerve membrane from the toxicity of homocysteine thiolactone 
modified low density lipoprotein and to directly activate the homocysteine ase 
of high density lipoprotein. 
118. Thierry C et al., “Neuroprotective Effect of Docosahexaenoic 
Acid–Enriched Phospholipids in Experimental Diabetic Neuropathy”. 
Docosahexaenoic acid phospholipids totally prevented the decrease in nerve 
conduction velocity  and  nerve blood ﬂow observed during diabetes when 
compared with the nonsupplemented diabetic group. Docosahexaenoic acid 
phospholipids also prevented the Na,K-ATPase activity decrease in red blood 
cell but not in sciatic nerve. Moreover, docosahexoaenoic level in sciatic 
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nerve membranes was correlated with nerve conduction velocity.These 
results demonstrate a protective effect of daily doses of docosahexaenoic 
acid on experimental diabetic neuropathy. Thus, treatment with 
docosahexaenoic acid phospholipids could be suitable for evaluation in 
clinical trials. 
119. Abhishek Bhanot et al., “A comparative profile of methanol 
extracts of Allium cepa Allium sativum in diabetic neuropathy in mice”. The 
results of the present study show that the extract of the outer scale of onion 
and the edible portion of both onion and garlic provided significant production 
in diabetic neuropathy in both preventive and curative groups. The methanol 
extract of the outer scales of onion has shown a most significant effect which 
may be due to the presences of higher quantities of phenolic compounds. 
120. Trupti C et al., “Protective effect of ethyl acetate soluble fraction of 
ethanolic extract of Terminalia Chebula Retz. fruits on diabetic neuropathy in 
mice”. In the present study, diabetic animals shows elevated blood glucose 
level, reduced pain threshold and motor incoordination. EATC treatment 
restored body weight, blood glucose, along with pain threshold and motor 
coordination in diabetic mice.   
121. Huda I Abd Elhafiz et al., “The Protective Effect of Calcitriol on 
Diabetic Neuropathy in STZ-induced Diabetic Rats”. Our study shows that 
calcitriol improved physiologic symptoms of neuropathy in diabetic rats. Also, 
it should be mentioned that co administration of calcitriol with insulin has the 
most positive effects on some indices of diabetic neuropathy. Results of the 
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current study suggest that calcitriol could have a potential therapeutic role in 
diabetic neuropathy. 
122. Naveen Kumar Gupta et al., “Neuroprotective potential of 
Azadirachta indica leaves in diabetic rats”. Neuropathic pain or hyperalgesia 
is a manifestation of diabetic neuropathy severs studies have reported 
oversentivity(feeling of excessive pain) in diabetic patients and animals. 
Presently diabetic animals exhibited decrease in threshold for pain perception 
and reported hyperalgesia. Hyperalgesia develops mainly due to local 
metabolic and microvascular changes in the nervous tissue.The involvement 
of superoxide ,peroxynitrite and hydroxyl radicals has already been well 
established in various animal model of hyperalgesia. Besides this the role of 
cytokines and inflammatory makers cannot be ignored in neuropathic pain 
and diabetic complications. The results of this study also revealed metabolic 
changes and variation in the antioxidant profile of diabetic animals. Thus 
alternations in the biochemical parameters seem to be akin with 
microangiopathic effects which suggested the development of hyperalgesia in 
diabetic animals. However the ALE treatment decreased reduction in neuronal 
inflammation, LPO, increased GSH content suggested reduction in neuronal 
stress levels hence attenuated the hyperalgesia. Thus in totally this study 
suggests the oral administration of ALE to STZ induced diabetic animals 
resulted in neuroproduction against degenerative oxidative stress associated 
with metabolic and histopathological changes.     
123.G.Sumithira , A.Ashmaet al., Evaluation of Neuroprotective Effect 
of PlecospermumSpinosum Trec in Experimentally induced Diabetic 
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Neuropathic pain in Rats. In this study revealed that Plecospermum Spinosum 
extract was proposed that in addition to its antidiabetic, the antioxidant 
properties is the prominent features in attenuation of diabetes induced 
neuropathy and its generating pain. These findings suggest that 
Plecospermum Spinosum treatment must be beneficial to treat pain in diabetic 
animals. 
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3. PLANT DESCRIPTION 
Name   : Ottelia alismoides (L.) Pers. 
Synonym   : Stratiotes alismoides  
                                            Damasonium alismoides 
 Family   : Hydrocharitaceae 
Vernacular names124-125:  
Common name  : Duck lettuce, Waterplantain. 
Tamil name   : Nirkuliri 
Malayalam   : Ottel ambel  
Kannada   : Hasiru neeru paathre 
Bengali   : Parmikalla  
Marathi   : Olek-alsem  
Telugu   : Edukula thaamara, Neeru veniki  
Dutch    : Duikerbloem 
Malaya   : Keladi Ayer 
Spanish   : Espada,Tangila 
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TAXONOMY126: 
Kingdom    : Plantae 
Subkingdom   : Tracheobionta 
Super division  : Spermatophyta 
Division   : Magnoliophyta 
Class    : Liliopsida 
Subclass   : Alismatidae 
Order    : Hydrocharitales 
Family   : Hydrochritaceae 
Genus   : Ottelia Pers 
Species   :Ottelia alismoides (L.) Pers 
CULTIVATION AND COLLECTIONS127-132: 
It grows in shallow waters, ponds and in rice fields. It faces no major 
threats and is therefore listed as Least Concern. It does well under strong light 
and harder water with a rich substrate. It is an annual and grows from seed 
each year. CO2 fertilisation and pH control make growing this plant in the 
aquarium less difficult. It grows very large in the aquarium and is best used as 
a feature plant. seeds may remain viable for up to four years noted that fish 
prefer to eat the seeds, but it is unknown how this affects germination Seeds 
will germinate in 25-30 °C, and germination may be influenced by light 
availability and burial depth, but substratum (mud or sand) and oxygen 
availability had no significant effect. 
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DESCRIPTION:    
      
Fig No :10           Fig No :11 
     
  Fig No :12                                           Fig No :13 
       
                    Fig No:14      Fig No:15 
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Habitat:  
This species grows in streams, lakes, marshes, ponds, ditches, 
canals14. Depth and turbidity of water affecting the penetration of light a clayey 
and reducing substratum and little biotic disturbance.(Fig no : 10).  
Leaves:  
Leaves are extremely variable, with short or long petioles according to 
the depth of the water. Blades of the submerged leaves are often narrow; the 
floating ones, ovate or somewhat rounded, with a rounded or often heart 
shaped base, thin and translucent  5 to 20 centimeters long. (Fig no : 11). 
Flowers:  
Flowers are white about 2cm in length Inflorescences 1-flowered; 
spathes 3-10 winged. Flowers sepals 10-15, stamens 3-12; ovary 1, 3-9 
carpellate. wrapped within spathes, cylindrical structures 2-4 cm long, 
composed of green bracts that are ornamented with 3 or more ruffled wings. 
Spathes born on long, angled stalks that become spiraled after flowering. 
Sepals and short-lived petals of male flowers exert from the tip of the spathe 
just above the water surface. Spathes containing female and/or bisexual 
flowers are self fertile and remain submersed. Petals white, pink, blue or 
purple, often tinged with yellow at the base. Flowering period autumn to 
spring. (Fig no : 12).  
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Fruit: 
Fruit is oblong, 2.5 to 4 centimeters long, ovoid to cylindrical and 
Fleshy encapsulated fruits contain as many as 2000 seeds Fruit with 
numerous  seeds(Fig no : 13). 
Seeds:  
Seeds densely covered with whitish, unicellular hairs. Seeds fusiform 
1–2 mm long, 0.3–0.7 mm in diameter, with 2 faint slightly curved longitudinal 
ridges. Testa light brown, dull to semi glossy, faintly wrinkled, with a tuft of 
unicellular white hairs. Hilum inconspicuous. Embryo linear-spatulate 
endosperm absent.( Fig no : 14). 
Stems & Roots: 
Stem small and corm-like, occasionally forked, with fibrous roots .The 
roots in the sediment in water to 2 feet deep and has short. (Fig no : 15).  
DISTRIBUTION133-134: 
Ottelia alismoides (L.) pers. is Widely distributed in northeastern Africa, 
South Korea, eastern and southeast Asia and the tropical regions of Australia, 
Bangladesh. It is introduced in United states china (Anhui, Fujian, 
Guangdong, Guangxi, Guizhou, Hainan, Hebei, Heilongjiang, Henan, Jiangsu, 
Jiangi, Jilin, Liaoning, Sichuan, Yunnan, Zhejiang),Egypt, Hong Kong, India, 
Srilanka. It has been reported from many countries across tropical and 
subtropical Asia and Australia and covers a wide geographic range. It is found 
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throughout India in tanks, ponds, streams and ditches. It was identified in 
several places like the aquatic herb at the back waters of Madhuban Dam 
near Dudhani, Silvassa region and  Kunnathur tank Madurai. The plant was 
identified in the location of Agaram village kudapakkam villianur Pondicherry.   
PHYTOCHEMISTRY135-139:   
Phytochemical present in this genus contain different natural 
compounds like glycosides, Alkaloids, Flavonoids, Terpenoids, Tannins,  
Phenolic compounds. Present knowledge about this endangered species of 
medicinal plant is still limited with respect to its phytochemistry and biological 
activity. Major chemical constituents of Ottelia alismoides Studies revealed 
that isolated two diastereomeric 4-methylene-2-cyclohexenones, otteliones A 
and B, ten new diarylheptanoids (2,3,4,5a-d,6,7&8) together with a 
hydroxylated  analog of otteliones A and B and 3a-hydroxyottelione. 
ETHANOBOTANICAL  AND  MEDICINAL USES140: 
The plants are used to improve the water quality in fish ponds by 
capturing floting mud particles. The petioles and leaves are eaten as a 
vegetable with excellent flavour, the leaves are used in Thailand for 
seasoning rice. The fruit is also edible. The plant is used in the treatment of 
haemorrhoids and applied as the poultice against fever. It is also grown as an 
aquarium plant 
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Table:1 Summarises the traditional use of different parts of the plant for 
various ailments. 
Plants part Uses/ailments 
Leaves 1. Applied on poultice arm & leg in fever, Topical for 
     haemorrhoids. 
2. Decoction of ground leaves mixed with shoots of ipomoea 
    aquatic, alium sativum, lasia spinosa, ocimum sanctum 
    and Typha angustata for the treatment of pneumonia. 
3. It is used as a rubefacient.  
4. It is used as the treatment of stomach disorder. 
5. It is used as spice for the rice and vegetables.  
6. Leaves used to check bleeding. 
 
Flowers 
1. Flower paste 10-12 gram is taken orally early in morning 
    to curing piles.  
2. Local people eat lower part of the flower as raw or as 
    vegetable.  
Fruit 1. Arresting cough and inducing diuresis.  
2. Fruit eaten as raw. 
Whole plant 1. It is a promising drug raw material having anti-tuberculosis 
    activity.  
2. Plant prepared as paste and applied to abscesses of the 
    breasts cancer, ulcers and burns. 
3. It is also used for treatment of Asthma and applied 
    externally for skin diseases.  
4. Clearing away from heat. 
5. Eliminating phlegm 
6. It is used for the treatment of diabetes.  
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Earlier work done on Ottelia alismoides (L.) Pers., 
1. Li H, Qu X, Zhao D et al., Preliminary study on the anti-tubercular 
effect of Ottelia alismoides (L.) Pers. In this study a clinical trials, extract of 
Ottelia alismoides cured two cases of bilateral tuberculosis of cervical lymph 
glands within 3 months. Results suggest Ottelia alismoides to be a promising 
medicinal herb with anti-tubercular effect. 
2. Seif-Eldin, Ayyad N et al., Otteliones A and B: potently Cytotoxic  
4-Methylene-2-cyclohexenones from Ottelia alismoides. In this study Isolated 
Ottelione A the natural products showed remarkable in vitro cytotoxicity 
against various cancer cell lines 
3. Tsai-Yuan Chang, Yun-Peng Tu et al., Synthesis and 
Antiproliferative Activities of Ottelione A Analogues. In this study Ottelione A, 
isolated from the fresh water plant Ottelia alismoides, is among the most 
potent natural product that possess in vitro antiproliferative activity, with an 
IC50 in the pM-nM range against 60 human cancer cell lines. Study 
established the relationship of antimitotic ottelione against tubulin and various 
cancer cell lines.  
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4. SCOPE OF THE PRESENT STUDY 
In the present situation, diabetes is possibly the world’s largest growing 
metabolic disorders and as the knowledge on the heritogeneity of this disorder 
is advanced, the need for more appropriate therapy increases. People with 
diabetes can over time develop nerve damage throughout the body. About 60-
70 % of people with diabetes have neuropathy. A number of allopathic drugs 
are used for the diabetic neuropathy effect like Aceclofenac, Aspirin, 
Gabapentin, Paroxetine and Imipramine which have danger of drug 
interaction, adverse effects etc. Traditional plant medicines are used 
throughout the world for a range of diabetic neuropathy presentations. There 
are many medicinal plants known to be used in the treatment of diabetic 
neuropathy and a number of plants had been screened positively for their 
Diabetic neuropathy effect. Most of these plants were found to belong to the 
chemical group glycosides, alkaloids and Flavanoids and Tannins. 
Ottelia alismoides(L.) PERS whole plant is having the Diabetic 
neuropathy activity. As per the literature review, still no Diabetic neuropathy 
activity has been reported on this plant. Hence, this study has been taken to 
explore the Diabetic neuropathy activity of Ottelia alismoides. In 
Streptozotocin induced diabetes in Wistar albino rats. 
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5. AIM AND OBJECTIVES 
Aim  
 The present investigation was aimed to screen the Diabetic neuropathy 
activity of Ottelia alismoides (L.) PERS on Streptozotocin induced Diabetic 
Wistar albino rats. 
Objectives 
The objective of the present study to: 
a. Find out the phytochemical constituents present in the ethanolic 
extract of the whole plant of Ottelia alismoides (L.) PERS 
b. Acute toxicity studies 
c. Evaluation of anti-diabetic activity 
 Blood glucose level 
 Body Weight 
 Organ Weight (Liver and Kidney) 
d. Estimation of  Antioxidant parameters 
 Superoxide dismutase level (SOD) 
 Catalase level (CAT) 
 Reduced glutathione (GSH) 
 Glutathione peroxidase (GPx) 
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Other parameter: 
 Na+ ,K+, ATPase acivity 
e. Estimation of Oxidative stress parameters 
 Lipid peroxidation (LPO) 
f. Estimation of Behavioral assessment parameters 
 Hot plate (Thermal Hyperalgesia) 
 Cold plate (cold allodynia) 
 Tail immersion (Thermal hyperalgesia) 
 Tail clip (Mechanical hyperalgesia) 
 Tail Flick (Thermal hyperalgesia) 
 Formalin (Chemical hyperalgesia) 
g. Histopathological studies of sciatic nerve 
h. Statistical analysis 
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6. PLAN OF WORK 
1. Collection of plant. 
2. Authentication of plant, shade drying of the Whole plant. 
3. Extraction of plant materials with solvents. 
4. Preliminary phytochemical screening of Ethanolic extract of Whole 
plant of Ottelia alismoides (L.) PERS 
5. Evaluation of acute toxicity studies to determine LD50 value 
6. Evaluation of anti-diabetic activity. 
7. Estimation of Nociceptive threshold parameters. 
8. Histopathological study of sciatic nerve. 
9. Statistical analysis                   
  
  
Dept. of Pharmacology, The Erode College of Pharmacy & Research Institute  68 
7. MATERIALS AND METHODS 
7.1 PLANT MATERIALS: 
7.1.1 Collection and authentication, shade drying and granulation of 
plant material 
 The whole plant Ottelia alismoides (L) PERS., were collected in the 
month of February from Agaram Village Kudapakkam Villianur Pondicherry. 
The plant material was taxonomically identified and authenticated by 
Dr.N.Ayyapan Researcher, French Institute of Pondicherry, Pondicherry. 
7.2 PREPARATION OF OTTELIA ALISMOIDES ETHANOLIC EXTRACT 
  The whole plant of Ottelia alismoides(L) PERS. were dried under 
shade and then powdered with a mechanical grinder. The powder was passed 
through sieve No:40 and stored in an airtight container for further use. 
7.2.1 Method of Extraction 
Soxhlet extraction: 
Soxhlet extraction is the process of continuous extraction in which the 
same solvent can be circulated through the extractor for several times. This 
process involves in the extraction followed by evaporation of the solvent. The 
vapours of the solvent are taken to a condenser and the condensed liquid is 
returned to the drug for continuous extraction.  Soxhlet apparatus designed 
for such continuous extraction consists of a body of extractor attached with a 
side tube and siphon tube. The lower of the extractor is attached to distillation 
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flask and the mouth of extractor is fixed to a condenser by the standard joints. 
The powdered crude drug is packed in the soxhlet apparatus directly or in a 
thimble of filter paper or fine muslin cloth. The diameter of the thimble 
corresponds to the internal diameter of the soxhlet extractor.  
7.2.2 Chemicals and preparation of drug solutions: 
Streptozotocin was obtained from Sisco research laboratories Pvt. Ltd, 
Mumbai, India and Pregabalin was perchased from Swapnaroop drugs & 
pharmaceuticals, Aurangabad, Maharastra, India. All otherchemicals and 
reagents used were of analytical grade. 
7.3 PRELIMINARY PHYTOCHEMICAL SCREENING 
Qualitative Phytochemical Analysis141 
          The Ethanolic extract of Ottelia alismoides was analyzed for the 
presence of various phytochemical constituents. 
A.CARBOHYDRATE TESTS 
1.Molisch’s test: 
 To the test solution, few drops of α-naphthol was added, then few 
drops of concentrated sulphuric acid was added  through the sides of test 
tube, purple to violet colour ring appeared at the junction, indicates the 
presence of carbohydrates. 
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2.Fehling’s test: 
To the test solution, equal quantity of Fehling’s A and B were added 
and heated on water bath, brick red precipitate was formed, indicates the 
presence of carbohydrates. 
3.Benedict’s test: 
To the test solution, 5ml of Benedict’s reagent was added and heated 
on water bath, red precipitate was formed, indicates the presence of 
carbohydrates. 
4.Barfoed’s test: 
To 1 ml of the test solution, add 1ml of Barfoed’s reagent was added 
and heated on a water bath, red cupric oxide was formed, presence of 
monosaccharide. 
5.Test for pentoses: 
To the test solution, equal volume of hydrochloric acid and 
phloroglucinol was added and heated, no red colour was produced, indicates 
the absence of pentoses. 
6.Selivanoff’s test (test for ketones): 
To the test solution, crystals of resorcinol and equal volume of 
concentrated hydrochloric acid were added and heated on a water bath, rose 
colour was produced, indicates the presence of ketones. 
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B.ALKALOIDS 
1.Dragendroff’s test: 
To 1ml of the extract, Dragendroff’s reagent (potassium bismuth iodine 
solution) was added, no reddish brown precipitate was formed, indicates the 
absence of alkaloids. 
2.Wagner’s test: 
To 1ml of the extract, Wagner’s reagent (iodine potassium iodide 
solution) was added, no reddish brown precipitate was formed, indicated the 
absence of alkaloids. 
3.Mayer’s test: 
To 1 ml of the extract, Mayer’s reagent (potassium mercuric iodine 
solution) was added, no cream colour precipitate was formed, indicates the 
absence of alkaloids. 
4.Hager’s test: 
To 1 ml of the extract, Hager’s reagent (saturated aqueous solution of 
picric acid) was added, no yellow coloured precipitate was formed, indicates 
the absence of alkaloids.  
5.Tannic acid test: 
To the extract tannic acid solution was added, no buff colour precipitate 
was produced, indicates the absence of alkaloids. 
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C) GLYCOSIDE TEST 
1.Legal’s test: 
The extract in pyridine and sodium nitroprusside solution was added to 
make it alkaline, formation of pink to red colour showed the presence of 
glycosides. 
2.Baljet’s test: 
To 1 ml of the extract, 1 ml of sodium picrate solution was added and 
the change of yellow to orange colour reveals the presence of glycosides. 
3.Borntrager’s test: 
Few ml of dilute sulphuric acid was added to 1 ml of the extract 
solution. Boiled and filtered and then the filtrate was extracted with 
chloroform. The chloroform layer was treated with 1 ml of ammonia. The 
formation of red colour of the ammonical layer showed the presence of 
anthraquinone glycosides. 
4.Keller killani test: 
1. 1gm of powdered drug was extracted with 10ml of 70% alcohol for 2 
minutes, filtered, the filtrate was added to 10 ml of water and 0.5 ml of strong 
solution of lead acetate and filter, and the filtrate was shaken with 5ml of 
chloroform. 
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2. The chloroform layer was separated in a porcelain dish and the solvent 
was removed by gentle evaporation. The cooled residue was dissolved in 3 ml 
of glacial acetic acid containing 2 drops of 5% ferric chloride solution. 
The solution was carefully transferred to the surface of 2ml of 
concentrated sulphuric acid. A reddish brown layer formed at the junction of 
the two liquids and the upper layer slowly became bluish green, darkening 
with standing. 
D.TEST FOR SAPONINS 
1. Foam test: 
 Small quantity of alcoholic extract was taken and 20ml of distilled water 
was added and shaked in a graduated cylinder for 15 minutes length wise. No 
Layer of foam, indicates the absence of saponins. 
E. TEST FOR FLAVANOIDS 
1. Shinoda’s test: 
To the test solution, few magnesium turnings were added and 
concentrated hydrochloric acid was added drop wise, pink scarlet, crimson 
red or occasionally green to blue colour appeared after few minutes indicating 
the presence of flavanoids. 
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2. Alkaline reagent test: 
To the test solution, few drops of sodium hydroxide solution was 
added, intense yellow colour was formed which turned colourless on addition 
of few drops of dilute acid indicating presence of flavanoids. 
3. Zinc hydrochloride test: 
To the test solution, a mixture of zinc dust and concentrated 
hydrochloric acid were added. It gave red colour after few minutes showing 
the presence of flavanoids. 
F. TEST FOR TANNINS 
1. Ferric chloride test: 
To the test solution, ferric chloride solution was added, green colour 
appeared showing the presence of condensed tannins. 
2. Phenazone test: 
To the test solution, 0.5 grams of sodium phosphate was added, 
warmed and filtered. To the filtrate 2% phenazone solution was added, bulky 
precipitate was formed which was often coloured, indicating the presence of 
tannins. 
3. Gelatin test: 
To the test solution, 1% gelatine solution containing 10% sodium 
chloride was added. Precipitate was formed, indicating the presence of 
tannins. 
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4. Test for Catechin: 
Match stick was dipped in the test solution, it was dried and lastly 
moistened with concentrated hydrochloric acid. Then the stick was warmed 
near to flame. The colour of the wood changed to pink due to phloroglucinol. 
(Phloroglucinol was formed when catechins were treated with acids), 
indicating the presence of tannins. 
7.4 ACUTE TOXICITY STUDY 
 Organisation for Economic co-operation and Development (OECD) 
regulates guidelines for oral acute toxicity study. It is an international 
organisation which works with the aim of reducing both the number of animals 
and the level of pain associated with acute toxicity testing. To determine the 
acute oral toxicity OECD frames the following guideline methods. 
 OECD 401 – Acute Oral Toxicity 
 OECD 420 – Acute Oral Toxicity: Fixed Dose procedure 
 OECD 423 –Acute Oral Toxicity: Acute Toxic Classic method 
OECD 425 – Acute Oral Toxicity: Up and own Procedure 
In the present study the acute oral toxicity of Ottelia alismoides was 
carried out according to OECD 423 guideline (Acute Oral Toxicity: acute Toxic 
Classic Method). 
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ANIMALS: 
Male Swiss albino mice weighing between 20 – 25 gm was used for the 
study. The animals were obtained from animal house, Nandha College of 
Pharmacy, Erode. The animals were placed at random and allocated to 
treatment groups in polypropylene cages with paddy husk as bedding. 
Animals were housed at a temperature of 24±2oC and relative humidity of 30 
– 70 %. A 12:12 light: day cycle was followed. All animals were allowed to free 
access to water and fed with standard commercial pelleted rat chaw. All the 
experimental procedures and protocols used in this study were reviewed and 
approved by the Institutional Animal Ethics Committee of Nandha College of 
Pharmacy. (IAEC No: NCP/IAEC 2016-17-18) and were in accordance with 
the guidelines of the CPCSEA. 
Acute Toxicity Studies: 
 Acute toxicity studies were performed according to OECD-423 
(Organization of Economic and Cooperation Development) guidelines. Male 
Swiss mice selected by random sampling technique were employed in this 
study. The animals were fasted for 4h with free access to water. The 
Ethanolic extract of Ottelia alismoides (EEOA) was administered orally at a 
dose of 5 mg/kg initially and mortality if any was observed for first 24 hrs and 
after 72 hrs. If mortality was observed in two out of three animals, then the 
dose administered was considered as toxic dose. However, if the mortality 
was observed in only one animal out of three animals then the same dose 
was repeated again to confirm the toxic effect. If no mortality was observed, 
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then higher (50, 300, 2000 mg/kg) doses of the plant extracts were employed 
for further toxicity studies. 
OBSERVATION: 
The following general behaviour was also observed during the acute toxicity 
study (Ecobichon DJ, 1997)142. 
1. Sedative 
2. Hypnotics 
3. Convulsion 
4. Ptosis 
5. Analgesia 
6. Stupar reaction 
7. Motor activity 
8. Muscle relaxant 
9. Pilo erection 
10. Change in skin colour 
11. Lacrimal secretion 
12. Stool Consistency 
Result: 
There was no mortality with the extract of Ottelia alismoides after 24 & 
72 hrs even at (2000mg/kg). The extract did not alter the general behaviour in 
mice. No lethality or toxic reactions were found during and after the study 
period. 
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7.5 EXPERIMENTAL INDUCTION OF DIABETES  
Sterptozotocin Induced Diabetes: 
 A freshly prepared solution of STZ (55 mg/kg in 0.01 M citrate buffer, 
pH 4.5) was injected intraperitoneally to overnight-fasted rats. The rats 
exhibited hyperglycaemia within 48 h of STZ administration. The rats having 
fasting blood glucose (FBG) values of 250 mg/dl or above were considered for 
the study. The study of test compound and standard drugs were dissolved in 
distilled water and administered orally with the help of gastric oral tube.  
7.5.1 EXPERIMENTAL DESIGN 
The Diabetic Neuropathy activity was tested on a total of 30 rats (24 
diabetic rats and 6 normal rats) and they were divided into five groups and 
each group consists of 6 animals as follows, 
Group I - Diabetic control received Streptozotocin injection (55mg/kg; b.wt; 
      i.p), freshly prepared in citrate buffer.                    
Group II- Streptozotocin injection (55mg/kg; b.wt; i.p) + insulin (5 IU/kg, 
                i.m). 
Group III- STZ+insulin+ Standard drug Pregabalin (15mg/kg) dissolved in 
      0.5% CMC. 
Group IV- STZ+insulin+ plant extract low dose (200mg/kg, b.wt; p.o)  
        suspended in 0.5% CMC. 
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Group V- STZ+insulin+ plant extract high dose (400mg/kg, b.wt; p.o) 
                  suspended in 0.5% CMC. 
In the first four weeks of the study all the groups were left untreated. 
From week 4 onwards the drug treatment started and continued up to the 
week 8 after STZ injection. Body weight and Behavioural assessments like 
thermal hyperalgesia (hot plate, tail flick & Tail immersion), Mechanical 
hyperalgesia (Tail clip) thermal allodynia (cold plate) & (chemical 
hyperalgesia) formalin were performed on week 0th, 4th, 6th & 8th of the study. 
At the end of 8th week the blood was collected by retro-orbital sinus puncture, 
rats were sacrificed by cervical dislocation organs collected and isolated 
sciatic nerves were analyzed for following Biochemical and histopathological 
study.  
Blood Sample and Organs Collection: 
The blood was collected by retro orbital under mild ether anaesthesia 
from overnight fasted rats, into tubes containing potassium oxalate and 
sodium fluoride as anticoagulant for estimation of fasting plasma glucose. 
Plasma and serum were separated by centrifugation. After centrifugation at 
2,000 rpm for 10 minutes, the clear supernatant was u sed for the analysis of 
various biochemical parameters. After collection of blood, all the treated 
animals were sacrificed the Sciatic nerve and liver tissues were isolated and 
rinsed in ice- cold saline and kept in formalin solution (10%) for further 
histopathological studies & oxidative stress parameters. 
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Nerve collection and preparation of homogenate: 
After 8 weeks of experiment, sciatic nerve was removed bilaterally from 
the inguinal ligament to its trifurcation and incubated in triton x 100 for 20 min 
to remove blood from sciatic nerve. Sciatic nerves were chopped into small 
pieces and then homogenized with phosphate buffer solution (pH 7.0) by 
using homogenizer. The homogenate was then centrifuged in a cold 
centrifuge (Thermo Scientific) at 4ºC, 4000 x g for 10 min. The resulting 
homogenate was passed through a cellulose filter to remove impurities and 
was aliquoted for the measurement of SOD, GSH, CAT, GPx, LPO, Na+, K+, 
ATPase activity. 
7.6 EVALUATION OF PARAMETERS143 
7.6.1 General parameters: 
Body weight and Organ weight: 
The body weight of rats was checked using a top loader weighing 
balance. The body weight is expressed in grams. The vital organs such as 
kidney and liver were collected. Blood was removed from the organs with the 
filter paper and their weights were assessed with an electric weighing 
balance. The organ weights were expressed in grams or milligrams. 
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7.7 EVALUATION OF BIOCHEMICAL PARAMETERS: 
7.7.1 Estimation of blood glucose level: 
The Blood glucose levels were estimated by Hexokinase method144. 
Glucose is phosphorylated by hexokinase (HK) in the presence of adenosine 
triphosphate (ATP) and magnesium ions to produce glucose-6- phosphate 
and adenosine diphosphate (ADP). Glucose-6-phosphate dehydrogenase 
(G6P-DH) specifically oxidises glucose-6-phosphate to gluconate-6-
phosphate with the concurrent reduction of NAD+ to NADH. The increase in 
absorbance at 340nm is proportional to the glucose concentration in the 
sample. 
 
 
Reagents 
Reagent 1: 
 0.05 M Tris HCl buffer, pH 8.0 with 13.3 mM MgCl2 
 0.67 M Glucose in Tris-MgCl2 buffer 
 16.5 mM ATP in Tris-MgCl2 buffer 
 6.8 mM NAD in Tris-MgCl2 buffer 
  
HK, Mg
2+
 
 Glucose + ATP                                       Glucose-6-phosphate + ADP 
 
Glucose-6-Phosphate + NAD
+                                 
Gluconate-6-P + NADH + H
+ 
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Reagent 1A: 
 300 IU/ml Glucose-6-phosphate dehydrogenase in Tris-MgCl2 buffer 
 300 IU/ml Hexokinase in Tris-MgCl2 buffer 
Procedure: 
  150 μl of reagent 1 was added with 30 μl of reagent 1A and to this 20 μl 
of suitable diluents was added and the contents were mixed thoroughly. To 
this mixture, 2 μl of serum sample was added. Then the contents were mixed 
and incubated at 37°C for 10 seconds. After zeroing the instrument with blank 
the absorbance of standard followed by the test sample was measured at 340 
nm. The values were expressed as mg/dl. 
7.8 EVALUATION OF NOCICEPTIVE PARAMETERS: 
7.8.1 Tail Flick Method: 
The tail flick test is a test of the pain response in animals, similar to 
the hot plate test. It is used in basic pain research and to measure the 
effectiveness of analgesics, by observing the reaction to heat. The 
quantitative measurements of pain threshold in animal against thermal 
radiation and for evaluation of analgesic activity. It was first described by D’ 
Amour and Smith in 1941145-146. 
PROCEDURE: 
The nociceptive response was evaluated regarding the latency to 
withdrawal of the tail in response to noxious radiant heating. Animals are 
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placed into individual restraining cages leaving the tail hanging out freely. The 
animals are allowed to adapt to the cages for 30 min before testing. The 
apparatus used is tail flick analgesiometer, the tip of tail of rat is placed on hot 
metal wire and latency of withdrawal is calculated manually by stop watchR. 
7.8.2 Tail Clip Method: 
The method was described by Haffner147. 
PROCEDURE: 
 Six screened Wister rats were assigned to each of the 5 groups. The 
drug was administered   30   min prior testing. An artery clip was applied to 
the root of the tail (approximately 1 cm from the body) to induce pain. The 
animal quickly responds to this noxious stimuli by biting the clip or the tail near 
the location of the clip. The time between stimulation onset and response was 
measured by a stopwatch in 1/10 seconds increments. The length of time until 
response indicates the period of greatest activity after dosing [Schleyerbach 
2002] in different period of treatments was recorded. The values of 
prolongation of latency time of experimental groups were compared with 
control group for statistical analysis. 
7.8.3 Hot Plate Method: 
The method originally described by Woolfe and MacDonald148 (1944) 
.The paws of the rats are very sensitive to heat at temperatures which are not 
damaging the skin. The responses are jumping, withdrawal of the paws and 
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licking of the paws. The time until these responses occur is prolonged after 
administration of centrally acting analgesics.  
PROCEDURE: 
In this hot plate method animals from the each group were placed on 
the hot plate (Eddys hot plate) which is commercially available consists of an 
electrically heated surface. Temperature of this hot plate is maintained at 55 ̊ 
C- 56 ̊ C. This can be a copper plate or a heated glass surface. The 
observation is done up to the time until paw licking or jumping was noted the 
cut- off time was 10 sec. The reaction time was noted after the oral 
administration of the drugs and test compounds. 
7.8.4 Formalin Test: 
The formalin test in rats has been proposed as a chronic pain model 
which is sensitive to centrally active analgesic agents by Dubuisson and 
Dennis149-150(1977).The formalin test uses a 10% formalin solution as a 
chemical noxious stimulus. By injecting the formalin solution into the paw of a 
rat, a model of persistent (chronic) pain caused by peripheral tissue injuries 
and inflammation is created.  
PROCEDURE 
At the end of the study, all the groups were subjected to the formalin 
test. Briefly, each rat was acclimatized to the observation box before the 
formalin test. After an adaptation period of 15 min, the right hind foot paw was 
injected with 50 mL of 2.5% formalin in the intraplantar region. Nociception 
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was evaluated by quantifying paw licking time   during the first 10 min (acute 
phase) and at 20– 40 min (delayed phase) (Khalilzadeh et al., 2008; Luiz et 
al., 2007) 
7.8.5 Cold Plate Method: 
A cold plate apparatus was designed to test the responses of 
unrestrained rats to low temperature stimulation of the plantar aspect of the 
paw. At plate temperatures of 10 degrees C and 5 degrees C, rats with either 
chronic constriction injury (CCI) of the sciatic nerve or complete Freund's 
adjuvant (CFA) induced inflammation of the hind paw displayed a stereotyped 
behavior. Brisk lifts of the treated hind paw were recorded, while no evidence 
of other nociceptive behaviors could be discerned151. 
Procedure: 
Cold-plate tests were conducted to evaluate the hyperalgesic 
responses to cold stimuli. For this test, the hot/cold-plate test device (Ugo-
basile, 35100, Verase, Italy) was used. After setting the aluminium plate to 4 
1C71 1C, the rats were placed in the Plexiglas compartment. The time that 
elapsed between placing the animals in the device and the time point that 
they quickly withdrew their paws was recorded (Rosellini et al., 2012). The 
steps taken by the animals when walking or the slow paw-withdrawal behavior 
related to locomotion were not considered (Ortega-Álvaro et al., 2012). 
Measurements were repeated three times for each rat, and the average of 
these three values was calculated (Rosellini et al., 2012). To avoid paw 
damage, the experiment was not conducted for more than 30 s. 
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7.8.6 Tail Immersion Method: 
Hot and cold water Tail Immersion Test  
This method was described by Sharma et al., 2006a152. 
Procedure: 
 The procedure was based on the reaction time of the typical tail-
withdrawal reflex in rats induced by immersing the end of the tail in warm 
water of 52.5±1ºC and cold water of 10±0.5ºC. The lower portion of the tail, 
nearly 5 cm from tip, was marked and immersed in a beaker of freshly filled 
warm water and cold water. The rats reacted by withdrawing the tail in a few 
seconds. This reaction was measured two to three times, with an interval of at 
least 15min, in order to obtain two consecutive values that differed no more 
than 10%. After each determination, the tail was carefully dried. The cut-off 
time for warm water tail immersion was 15 s and cold water tail immersion 
30s.   
7.9 EVALUATION OF ANTIOXIDANTS PARAMETERS: 
7.9.1 Estimation Superoxide dismutase(SOD) 
         This enzyme catalyzes the dismutation of superoxide anion (O2-) to 
hydrogen peroxide and molecular oxygen in the following manner153. 
 
The enzyme activity was assayed by the method of Misra and Fridovich. 
  
H2O + 2O2-. + 2H+ → 2H2O2 + O2 
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Reagents: 
 0.1 M Carbonate-bicarbonate buffer; pH 10.2. 
 0.6 mM EDTA solution 
 1.8 mM Epinephrine (prepared in situ) 
  Absolute ethanol. 
 Chloroform 
Procedure: 
 0.1 ml of tissue homogenate was added to the tubes containing 0.75 ml 
ethanol and 0.15 ml chloroform (chilled in ice) and centrifuged. To 0.5 ml of 
supernatant, added 0.5 ml of 0.6 mM EDTA solution and 1 ml of 0.1 M 
carbonate-bicarbonate (pH 10.2) buffer. The reaction was initiated by the 
addition of 0.5 ml of 1.8 mM epinephrine (freshly prepared) and the increase 
in absorbance at 480 nm was measured. One unit of the SOD activity was the 
amount of protein required to give 50% inhibition of epinephrine autoxidation. 
7.9.2 Estimation of Catalase (CAT) 
                This enzyme catalyzes conversion of hydrogen peroxide into water 
and molecular oxygen154. 
 
  
The enzyme activity was assayed by the method of Sinha. 
  
2H2O2 → 2H2O + O2 
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Reagents: 
 Dichromate-acetic acid reagent: 5% potassium dichromate in water 
was mixed with glacial acetic acid in the ratio of 1:3 (v/v). 
 0.01 M Phosphate buffer; pH 7.0. 
 0.2M Hydrogen peroxide 
Procedure: 
             0.1 ml of the tissue homogenate was added to the reaction mixture 
containing 1ml of 0.01 M phosphate buffer (pH 7.0) pre-warmed to 37°C, 0.4 
ml of distilled water and the mixture was incubated at 37°C. The reaction was 
initiated by the addition of 0.5 ml of 0.2 M hydrogen peroxide and the reaction 
mixture was incubated at 37°C for one minute. The reaction was terminated 
by the addition of 2 ml of dichromate-acetic acid reagent after 15, 30, 45, and 
60 seconds. Standard hydrogen peroxide in the range of 4-20 μ moles were 
taken and treated in the same manner. All the tubes were heated in a boiling 
water bath for 10 minutes, cooled and the green colour that developed was 
read at 590 nm against blank containing all components except the enzyme. 
Catalase activity was expressed in terms of μ moles of H2O2 
consumed/min/mg protein. 
7.9.3 Estimation of Reduced glutathione (GSH): 
             The total reduced glutathione was determined according to the 
method of Ellman155. 
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  The assay procedure is based on the reduction of Ellman´s reagent [5, 
5΄- dithio dis (2- nitrobenzoic acid)] (DTNB) by SH groups of glutathione to 
form 2-nitro-S-mercaptobenzoic acid per mole of glutathione. The product is 
measured spectrophotometically at 412 nm. 
Reagents 
 0.2 M Phosphate buffer; pH 8.0. 
 0.6 mM DTNB reagent. 
 5%TCA  
Procedure 
0.1 ml of tissue homogenate was precipitated with 5% TCA. The 
contents were mixed well for complete precipitation of proteins and 
centrifuged. To 0.1 ml of supernatant, 2 ml of 0.6 mM DTNB reagent and 0.2 
M phosphate buffer (pH 8.0) were added to make up to a final volume of 4 ml. 
The absorbance was read at 412 nm against a blank containing TCA instead 
of sample. A series of standards treated in a similar way also run to determine 
the glutathione content. The amount of glutathione was expressed as 
nmoles/g tissue. 
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7.9.4 Estimation of Glutathione peroxide (GPx): 
Principle: 
GPx activity was assessed by modified method of Flohe and Gunzler 
(1984)156. 
Reagents:  
 Sodium phosphate buffer 0.3 M, pH 7.0  
 Sodium azide 1Omhl  
 Reduced glutathione 4mM  
 Hydrogen peroxide 2.5 mM  
 TCA lPh  
 Phosphate solution  0.3 M disodium hydrogen phosphate.  
 DTNB  40 mg/100 ml of 1% sod~um cihate  
 EDTA 0.8 mM 9. Standard 20 mg of reduced glutathione in 100 rnl 
distilled water. This solution contained 20 pg of glutathione/O. 1 ml. 
Procedure: 
 GPx activity was assessed by modified method of Flohe and Gunzler 
(1984). For the enzyme reaction, 0.2 ml of the post-mitochondrial supernatant 
was placed into a tube and mixed with 0.4 ml reduced glutathione and the 
mixture was put into an ice bath for 30 min. Then the mixture was centrifuged 
for 10 min at 3000 rpm, 0.48 ml of the supernatant was placed into a cuvette, 
and 2.2 ml of 0.32 M Na2HPO4 and 0.32 ml of 1.0 mmol/L DTNB were added 
for color development. The absorbance at wavelength 412 nm was measured 
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on spectrophotometer (LKB-Pharmacia, Mark II, Ireland) after 5 min. The 
enzyme activity was calculated as nmol/mg protein.  
7.10.EVALUATION OF OXIDATIVE STRESS PARAMETER 
Estimation of Lipid Peroxidation (LPO): 
            Lipid peroxidation (LPO) was assayed by the method of Ohkawa et 
al111, in which the malondialdehyde (MDA) released served as the index of 
LPO. The extent of LPO in the hepatic tissue was assayed by measuring one 
of the end products of this process, the thiobarbituric acid-reactive substances 
(TBARS). As 99% TBARS is Malondialdehyde (MDA), thus this assay is 
based on the reaction of 1 molecule of MDA with 2 molecules of TBARS at 
low pH (2- 3) and at a temperature of 95°C for 60 min. The resultant pink 
chromogen can be detected spectrophonometrically at 532nm157. 
Reagents  
 Standard: 1, 1, 3, 3-tetra ethoxypropane (TEP). 
 8.1% Sodium dodecyl sulphate (SDS) 
 20%Acetic acid 
 0.8%Thiobarbituric acid (TBA)  
 15:1 v/v n-butanol: pyridine mixture 
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Procedure 
           To 0.2 ml of tissue homogenate, 0.2ml of 8.1% SDS, 1.5ml of 20% 
acetic acid (pH 3.5) and 1.5 ml of 0.8% TBA were added. The mixture was 
made up to 4 ml with water and then heated in a water bath at 95.8ºC for 60 
min using glass ball as a condenser. After cooling, 1ml of water and 5ml of n-
butanol: pyridine (15:1 v/v) mixture were added and shaken vigorously. After 
centrifugation at 4000rpm for 10min, the organic layer was taken and its 
absorbance was measured at 532nm. The level of lipid peroxides was 
expressed as n moles of MDA formed/mg of protein. 
7.11.OTHER PARAMETER: 
 Estimation of NA+ , K+ , ATPase activity158-159.   
Principle: 
Na+/K+-ATPase activity was measured according to the method of 
Suhail and Rizvi 1987 The final assay mixture contained 0.5–1.2 mg 
membrane protein/mL, 20 mmol/L KCl, 140 mmol/L NaCl, 3 mmol/L MgCl2, 
30 mmol/L imidazole (pH 7.24), with or without 5 × 10–4 mol/L ouabain and 
6 mmol/L ATP. Assay mixture was incubated for 30 min at 37 °C and the 
reaction was stopped by the addition of 3.5 mL of a solution-A (0.5% 
ammonium molybdate, 0.5 mol/L H2SO4, and 2% sodium dodecyl sulphate). 
The amount of liberated phosphate (Pi) was estimated according to the 
method of Fiske and Subbarow (1925). 
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REAGENTS   
 0.5–1.2 mg membrane protein/mL,  
 20 mmol/L KCl, 140 mmol/L  
 NaCl, 3 mmol/L  
 MgCl2, 30 mmol/L 
 imidazole (pH 7.24), with or without 5 × 10–4 mol/L ouabain 
 f) nd 6 mmol/L ATP. 
Assay mixture was incubated for 30 min at 37 °C and the reaction was 
stopped by the addition of 3.5 mL of a solution-A (0.5% ammonium 
molybdate, 0.5 mol/L H2SO4, and 2% sodium dodecyl sulphate). The amount 
of liberated phosphate (Pi) was estimated and the values are recorded ( Fiske 
and Subbarow(1925).  Further  by adding  tissue extract to the above same  
assay mixture and incubated for 30 min at 37 °C and the Na+/K+-ATPase 
activity was measured in a spectrophotometer (Star 21 plus USA) and the 
activity  expressed as nmol pi released/mg protein per hour at 37 °C. 
7.12 HISTOPATHOLOGICAL STUDIES  
 Hematoxylin, a basic bye is oxidized to hematein with a mordant, a 
metallic ion suchas the salts of aluminium. The positively charged aluminium-
hematein complex combines with the negatively charged phosphate groups of 
the nucleic acids (DNA and RNA) forming blue/purple colour, which is 
characteristic of hematoxylin stains. Eosin is an acidic dye, which is 
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considered to have a selective affinity for the basic parts of the cell, i.e., the 
cytoplasm. Thus, the hematoxylin and eosin (H & E) stain is used to 
demonstrate different structures of the tissue160. 
 The various steps involved in the preparation of pancreatic tissues for 
histological studies are as follows: 
 Fixation: 
 In order to avoid tissue by the lysosomal enzymes and to preserve its 
physical and chemical structure, a bit of tissue from each organ was cut and 
fixed in bouin’s fluid immediately after removal from the animal body. The 
tissues were fixed in bouin’s fluid for about 24 hours. The tissues were then 
taken and washed in glass distilled water for a day to remove excess of picric 
acid. 
 Dehydration: 
 The tissues were kept in the following solutions for an hour each; 30%, 
50%, 70% and 100% alcohol. Inadequately dehydrated tissues cannot be 
satisfactorily infiltered with paraffin. At the same time over dehydration results 
in making the tissues brittle, which would be difficult for sectioning. So, careful 
precautions were followed while performing the dehydration process 
 Clearing: 
 Dealcoholization or replacement of alcohol from the tissues with a 
clearing agent is called as clearing. Xylene was used as the clearing agent for 
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one or two hours, two or three times. Since, the clearing agent is miscible with 
both dehydration and embedding agents, it permits paraffin to infilterate the 
tissues. So, the clearing was carried out as the next step after dehydration to 
permit tissue spaces to be filled with paraffin. The tissues were kept in the 
clearing agent till they become transparent and impregnated with xylene. 
 Impregnation: 
 In this process the clearing agent xylene was placed by paraffin wax. 
The tissues were taken out of xylene and were kept in molten paraffin 
embedding bath, which consists of metal pots filled with molten wax 
maintained at about 50oC. The tissues were given three changes in the 
molten wax at half an hour intervals. 
 Embedding: 
 The paraffin wax used for embedding was fresh and heated upto the 
optimum melting point at about 56–58oC. A clear glass plate was smeared 
with glycerine. L-shaped mould was placed on it to from a rectangular cavity. 
The molten paraffin wax was poured and air bubbles were removed by using 
a hot needle. The tissue was placed in the paraffin and oriented with the 
surface to be sectioned. Then the tissue was pressed gently towards the 
glass plate to make settle uniformly with a metal pressing rod and allowed the 
wax to settle and solidity room temperature. The paraffin block was kept in 
cold water for cooling. 
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 Section Cutting: 
 Section cutting was done with a rotatory microtome. The excess of 
paraffin around the tissue was removed by trimming, leaving ½ cm around the 
tissue. Then the block was attached to the gently heated holder. Additional 
support was given by some extra wax, which was applied along the sides of 
the block. Before sectioning, all set screws holding the object holder and knife 
were hand tightened to avoid vibration. To produce uniform sections, the 
microtome knife was adjusted to the proper angle in the knife holder with only 
the cutting edge coming in contact with the paraffin block. The tissue was cut 
Sin the thickness range of about 7µm. 
 Flattening and Mounting of Sections: 
 The procedure was carried out in tissue flotation warm water bath. The 
sections were spread on a warm water bath after they were detached from the 
knife with the help of hair brush. Dust free clean slides were coated with egg 
albumin over the whole surface. Required sections were spread on clean slide 
and kept at room temperature 
 Staining of Tissue Sections: 
 The sections were stained as follows; deparaffinization with xylene two 
time search for five minutes 
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Dehydration through descending grades of ethyl alcohol 
 100% alcohol (absolute) - 2 minute 
 90% alcohol - 1minute 
 50% alcohol - 1 minute 
 Staining with Ehrlich’s Haemaoxylin was done for 15-20 minutes. Then 
the sectioned tissues were thoroughly washed in tap water for 10 minutes. 
Rinsed with distilled water and stained with Eosin. Dehydration again with 
ascending grades of alcohol. 
 70% alcohol - 2 minute 
 90% alcohol - 2 minute 
 100%alcohol - 1 minute 
 Finally the tissues were cleared with xylene two times, each for about 3 
minutes interval. 
 Mounting: 
 On the stained slide, DPX mountant was applied uniformly and micro 
glass cover slides were spread. The slides were observed in Nikon 
microscope and microphotographs were taken. 
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7.13 STATISTICAL ANALYSIS 
The data of all the results were represented as Mean ± S.E.M. on 
statistically analysed by one-way ANOVA followed by Duncun’s Multiple range 
test was used for statistical analysis p<0.05 was considered significant161. 
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                                                   RESULTS 
 
Appearance and percentage yield of EEMP 
     Table No: 2 
Drug Ottelia alismoides (L.,) PERS 
Solvent Ethanol 
Colour Dark green 
Consistency Semi solid 
Percentage yield 19.5 % w/w 
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PRELIMINARY PHYTOCHEMICAL SCREENING 
Table No-3:  Results of the Preliminary Phytochemical Constituents 
present in Ethanolic extract of Ottelia alismoides(L) PERS.  
Table no: 3 Preliminary phytochemical constituents present in EEPS 
S. No Constituents 
Ottelia alismoides 
Ethanolic extract 
1. Alkaloids + 
2. Carbohydrates _ 
3. Protein _ 
4. Terpinoids + 
5. Phenols + 
6. Tannins + 
7. Flavanoids + 
9. Glycosides + 
10. Saponins _ 
+ve indicates the presence –ve indicates the absence 
RESULTS:  
The phytochemical constituents present in the Ethanolic extract of 
Ottelia alismoides (L.) PERS were Phenols, Tannins, Flavanoids, Glycosides, 
Alkaloids and Terpenoids. 
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Estimation of Blood glucose level: 
The Effect of the different doses of Ethanolic extract of Ottelia alismoides Pers 
on Blood Glucose level. 
Groups 
Blood glucose level(mg/dl) 
0th week 8th week 
Group I 
STZ(55mg/kg)+Vehicle 
330.15± 17.76 368.0± 59.05 
Group II 
STZ (55mg/kg)+ 
Insulin (5 IU/kg) 
341.10 ±22.31 160.10± 20.22*** 
Group III 
STZ+ insulin+ Pregabalin 
(15mg/kg) 
319.15 ±13.18 140.01± 17.02** a 
Group IV 
STZ+ insuln+ EEOA 
(200mg/kg) 
336.10 ±15.46 
120.08 ±13.15ns 
aa 
Group V 
STZ+ insulin+ EEOA 
(400mg/kg) 
317.10 ±12.18 
115.21 ±11.06ns 
aa 
 
Table no 4: Effect of EEOA on Blood Glucose level in experimentally induced Diabetic 
rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared to Insulin 
Diabetic control. 
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control group  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test 
(DMRT). 
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Fig.No. 16 Effect of EEOA on Blood Glucose Level in 
Experimentally induced Diabetic rat model 
 
Estimation of Body weight & Organ weight: 
The Effect of the different doses of Ethanolic extract of Ottelia alismoides Pers 
on Blood Glucose level. 
  Groups Body weight 
Organ weight 
Liver Kidney 
Group I 
STZ(55mg/kg)+Vehicle 
204.16±6.93 4.55±0.45 1.93±0.05 
Group II 
STZ +Insulin (5 IU/kg) 
249.06±5.31*** 3.09±0.34* 1.83±0.05* 
Group III 
STZ+ insulin+ Pregabalin 
(15mg/kg) 
248.31±5.30* 2.84±0.31ns 1.62±0.07ns 
Group IV 
STZ+ insuln+ EEOA 
(200mg/kg) 
240.56±5.29* 2.30±0.30ns 1.60±0.04ns 
Group V 
STZ+ insulin+ EEOA 
(400mg/kg) 
245.10±5.30a 3.08±0.50ns 1.56±0.04ns 
 
Table no 5: Effect of EEOA on Body weight & Organ weight in 
Experimentally induced Diabetic rat model 
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The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**, ***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared Insulin diabetic  
control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control  group 
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT). 
RESULTS: 
The Blood Glucose, Body weight and Organ Weight were measured 
and showed in Table no-3 & 4.  
The Diabetic control (Group 1) showed significant increase in Blood 
Glucose, Kidney weight & liver and whereas the body weight were decreased 
when compared insulin diabetic control (Group 2).  
Standard (Group 3) and EEOA (200 mg/kg& 400 mg/kg) showed 
statistically significant decrease in Blood Glucose and organ weight and 
increase in body weight when compared to Diabetic control (Group1).  
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ESTIMATION OF ANTIOXIDANT PARAMETERS 
Effect of  EEOA on Antioxidant level (SOD,CAT,GPx,GSH ) 
Groups 
SOD 
(units per mg 
protein ) 
CAT 
(units per mg 
protein) 
GPx 
(units per mg 
p rotein) 
GSH 
(units per 
mgprotein ) 
Group I 
STZ(55mg/kg)+Vehicle 
  1.627±1.06 1.08±0.09 1.13±0.05 1.26±0.54 
Group II 
STZ +Insulin (5 IU/kg) 
2.155±1.03*** 2.08±0.09*** 3.08±0.31*** 2.86±0.54*** 
Group III 
STZ+ insulin+ Pregabalin 
(15mg/kg) 
2.654±1.84** 2.16±0.11** 2.65±0.63** 2.86±0.54** 
Group IV 
STZ+ insuln+ EEOA 
(200mg/kg) 
2.431±1.86*a 2.24±0.31ns a 2.98±0.74ns a 3.14±0.31ns a 
Group V 
STZ+ insulin+ EEOA 
(400mg/kg) 
2.956±2.31 ns 
aa 
2.49±0.26 ns 
aa 
3.24±0.46 ns 
aa 
3.89±0.48 ns 
aa 
Table no 6: Effect of EEOA on Antioxidant level(SOD, CAT,GPx & CAT) 
in Experimentally induced Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared to insulin 
diabetic control 
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT). 
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Figure no 17: Effect of EEOA on Antioxidant level(SOD, CAT,GPx & GSH) in 
 Experimentally induced Diabetic rat model 
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RESULTS: 
The Superoxide dismutase (SOD), Catalase (CAT), Reduced 
glutathione (GSH), Glutathione peroxides (GPx) levels were measured and 
showed in Table no-6 and Fig. no-(17). 
The Diabetic control (Group 1) showed significant decrease in 
Superoxide dismutase (SOD), Catalase (CAT) and Reduced Glutathione 
(GSH) level when compared to the insulin diabetic control (Group 2). 
Standard (Group 3) and EEOA (200 & 400 mg/kg) showed statistically 
significant increase in Glutathione peroxidase (GPx), Superoxide dismutase 
(SOD), Catalase (CAT) and Reduced Glutathione (GSH) level when 
compared to diabetic control (Group 1). 
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ESTIMATION OF OXIDATIVE STRESS PARAMETER 
Effect of  EEOA on Malondialdehyde (MDA) level 
GROUPS LPO(units per mg protein) 
Group I STZ(55mg/kg)+vehicle 4.188±2.03 
Group II 
STZ +Insulin (5 IU/kg) 
3.86±2.03*** 
Group III 
STZ+ insulin  + Pregabalin (15mg/kg) 
3.256±1.84** 
Group IV 
STZ+ insulin+EEOA (200mg/kg) 
2.416±1.13ns a 
Group V 
STZ+ insulin+ EEOA (400mg/kg) 
2.136±1.39 ns aa 
 
Table no 7: Effect of EEOA on Malondialdehyde (MDA) level  
in Experimentally induced Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared diabetic control 
group 
a, aa indicates P < 0.05 & P < 0. 01 Significance between insulin diabetic treated group 
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT). 
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Figure  no 18: Effect of EEOA on Malondialdehyde (MDA) level  
in Experimentally induced Diabetic rat model 
RESULTS: 
The Liver Malondialdehyde (MDA) levels were measured and showed 
in Table no-7 and Fig. no-(17). The Diabetic control (Group 1) showed 
significant increase in Malondialdehyde (MDA) level when compared to the 
normal control (Group 2).  
Standard (Group 3) and EEOA (200&400 mg/kg) showed statistically 
significant decrease in Malondialdehyde (MDA) level when compared to 
Diabetic control (Group 1). 
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ESTIMATION OF  Na+ K+ ATP ase ACTIVITY: 
Effect of EEOA on Na+ K+ ATP ase Activity 
Group 
Na
+
/K
+
-ATPase activity 
(nmol pi released/mg protein per hour) 
Group I STZ(55mg/kg)+vehicle 2.634 ± 0.206 
Group II STZ+ 
Insulin (5 IU/kg) 
5.924±0.314*** 
Group III STZ+ insulin + Pregabalin 
(15 mg/kg) 
3.929±0.321** ns 
Group IV STZ+insulin+ EEOA 
(200mg/kg) 
5.026±0.234ns a 
Group V STZ+ insulin EEOA 
(400mg/ 
6.117±0.249ns aa 
 
Table no 8: Effect of EEOA on Na+ K+ ATP ase Activity  in Experimentally induced 
Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when diabetic control group 
a, aa indicates P < 0.05 & P < 0. 01 Significance between Insulin diabetic treated group  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 19  : Effect of EEOA on  in Na+ K+ ATP ase Activity  
Experimentally induced  Diabetic rat model 
RESULTS: 
The  Na+, K+ , ATPase  activity  were measured and showed in Table no-8 
and Fig. no-(19).The diabetic control (Group 1) showed significant decrease in 
Na+, K+ , ATPase activity  when compared to insulin diabetic control (Group1).  
Standard (Group 3) and EEOA (200&400 mg/kg) showed statistically 
significant increase in Na+, K+ , ATPase  activity  when compared to Diabetic 
control (Group 1) 
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BEHAVIOURAL ASSESMENT 
EFFECT OF EEOA ON HOT PLATE TEST:(Thermal Hyperalgesia) 
Groups 
 
Reaction Time in Sec 
0  Week 4
th
 Week 6
th
 Week 8
th
 Week 
Group I STZ 
(55mg/kg)+vehicle 
5.05 ± 0.84 4.46 ± 0.73 4.20 ± 0.27 3.91± 0.17 
Group II STZ+ 
Insulin (5 IU/kg) 
5.05  ± 0.31 *** 4.31 ± 0.67*** 4.11 ± 0.37*** 4.03 ± 0.54*** 
Group III STZ+ insulin + 
Pregabalin (15 mg/kg) 
5.05  ± 0.56** 
ns 
4.56 ± 0.16** 4.96 ± 0.56** 9.31 ± 0.16** 
Group IV STZ+insulin+ EEOA 
(200mg/kg) 
5.05  ± 0.31* a 4.60 ± 0.37* 4.70 ± 0.84ns a 9.54 ± 0.22ns  aa 
Group V STZ+ insulin EEOA 
(400mg/ 
5.05  ± 0.31ns  
a 
5.20 ± 0.18ns a 8.81 ± 0.16ns aa 10.87 ± 0.12ns aa 
 
Table no 9: Effect of EEOA on Hot plate test (Thermal hyperalgesia)  
in Experimentally induced Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*, **, ***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared to insulin 
diabetic control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 20 : Effect of EEOA on Hot plate test (Thermal Hyperalgesia) in   
Experimentally induced  Diabetic rat model 
RESULTS: 
The Paw Withdrawal latency were measured and showed in Table no-9 
and Fig. no-(20). The diabetic control (Group 1) showed significant decrease 
in Paw withdrawal latency when compared to the insulin diabetic control 
(Group 2).  
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in Paw withdrawal latency when compared to Diabetic 
control (Group 1). 
  
0
2
4
6
8
10
12
14
0 week 4th week 6th week 8th week
P
a
w
 w
it
h
d
ra
w
a
l 
(S
e
c
)
Group I  STZ
Group II  STZ (55mg/kg)+ Insulin (5 IU/kg)
Group III Pregabalin (15mg/kg)
Group IV EEOA (200mg/kg)
Group V  EEOA (400mg/kg)
  
Dept. of Pharmacology, The Erode College of Pharmacy & Research Institute  114 
EFFECT OF EEOA ON FORMALIN TEST: (Chemical hyperalgesia) 
Groups 
FORMALIN 
TEST(Acute phase) 
FORMALIN 
TEST(Delayed 
phase) 
Group I STZ 
(55mg/kg)+vehicle 
32.93±1.08 30.11±1.86 
Group II STZ+ 
Insulin (5 IU/kg) 
58.54±2.16 60.88±1.96*** 
Group III STZ+ insulin + 
Pregabalin (15 mg/kg) 
47.84±0.95 50.55±1.31aa 
Group IV STZ+insulin+ EEOA 
(200mg/kg) 
46.92±0.73 55.15±1.06aa 
Group V STZ+ insulin EEOA 
(400mg/ 
53.65±1.18 62.56±1.18aa 
 
Table no 10: Effect of EEOA on Formalin (chemical hyperalgesia) in Experimentally 
induced Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**, ***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared to insulin 
diabetic control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control group 
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 21 : Effect of EEOA on Formalin test (Chemical Hyperalgesia) 
in Experimentally induced  Diabetic rat model 
RESULTS: 
The response were measured and showed in Table no-10 and  
Fig. no-(21). The Diabetic control (Group 1) showed significant decrease in 
intensified nociceptive response and analgesic response when compared to 
the insulin diabetic control (Group 2).  
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in intensified nociceptive response and analgesic when 
compared to Diabetic control (Group 1). 
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EFFECT OF EEOA ON TAIL FLICK TEST: (Thermal Hyperalgesia) 
GROUPS 
Reaction Time In Sec 
0
th 
week 4
th
 week 6
th
 week 8
th
 week 
Group I STZ 
(55mg/kg)+vehicle 
4.23 ± 016 4.21± 0.27 4.13± 0.15 4.09 ± 0.627 
Group II STZ+ 
Insulin (5 IU/kg) 
9.22 ± 0.57*** 4.36 ± 0.19*** 4.21 ± 0.15*** 4.45 ± 6.27*** 
Group III STZ+ insulin + 
Pregabalin (15 mg/kg) 
5.93  ± 0.27** 
ns 
6.16 ± 0.31** 
ns 
7.93 ± 0.96** 
ns 
9.54 ± 0.73** ns 
Group IV STZ+insulin+ 
EEOA (200mg/kg) 
5.16 ± 0.16* 5.91 ± 0.22 ns 7.11 ± 0.54aa 9.6 ± 0.56aa 
Group V STZ+ insulin 
EEOA (400mg/ 
5.39  ± 0.23 *  6.11 ± 0.56a 8.27 ± 0.22aa 9.93 ± 0.73aa 
 
Table No11: Effect of EEOA on Tail Flick test (Thermal hyperalgesia)  
in experimentally induced Diabetic rat model   
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when insulin diabetic control 
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control group  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 22 : Effect of EEOA on Tail Flick test (Thermal Hyperalgesia)  
in Experimentally induced Diabetic rat model 
RESULTS: 
The Tail withdrawal latency (Sec) were measured and showed in Table 
no-11 and Fig. no-(22). The Diabetic control (Group 1) showed significant 
reduction in tail withdrawal latency when compared to insulin diabetic 
control(Group 2). 
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in reaction time when compared to the Diabetic control 
(group 1). 
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EFEECT  OF  TAIL IMMERSSION TEST: (Thermal hyperalgesia)  
Effect of EEOA on Hot waterTail Immerssion test (Thermal hyperalgesia) 
GROUPS 
Reaction Time in Sec 
0
th
 week 4
th
 week 6
th
 week 8
th
 week 
Group I STZ 
(55mg/kg)+vehicle 
10.31 ± 0.93 4.80 ± 0.24 4.98± 0.39 4.86 ± 0.29 
Group II STZ+ 
Insulin (5 IU/kg) 
5.56 ± 0.73*** 7.49± 0.27*** 6.13± 0.57*** 6.29 ± 0.11*** 
Group III STZ+ 
insulin + 
Pregabalin (15 
mg/kg) 
5.96 ±0.16**ns 8.11 ± 0.56** ns 
11.54 ± 0.67** 
ns 
3.08 ± 0.42** ns 
Group IV 
STZ+insulin+ 
EEOA (200mg/kg) 
6.03 ± 0.18* 6.94 ± 0.013 a 7.93 ± 0.63 aa 8.93 ± 0.56aa 
Group V STZ+ 
insulin EEOA 
(400mg/ 
6.13 ± 0.31* 7.11 ± 0.015 aa 8.76 ± 0.23 aa 11.57 ± 0.27aa 
Table no 12 : Effect of EEOA on Hot waterTail Immerssion test (Thermal hyperalgesia) 
in Experimentally induced  Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared insulin diabetic 
control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 23 : Effect of EEOA on Hot water Tail Immerssion test (Thermal 
Hyperalgesia) in Experimentally induced  Diabetic rat model 
RESULTS: 
The Tail withdrawal latency (Sec) were measured and showed in Table 
no-12 and Fig. no-(23). The Diabetic control (Group 1) showed significant 
reduction in tail withdrawal latency when compared to the diabetic control 
(Group 2). 
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in reaction time when compared to the Diabetic control 
(group 1). 
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Effect of EEOA on Cold waterTail Immerssion test (Thermal allodynia) 
GROUPS 
Reaction Time In Sec 
0
th
 week 4
th
 week 6
th
 week 8
th
 week 
Group I STZ 
(55mg/kg)+vehicle 
9.86 ± 0.67 5.36± 0.34 4.76 ± 0.13 1.13 ± 0.27 
Group II STZ+ 
Insulin (5 IU/kg) 
6.11 ± 
0.27** 
7.58 ± 0.16*** 6.53 ± 0.14*** 5.32 ±0.21*** 
Group III STZ+ insulin 
+ Pregabalin (15 
mg/kg) 
6.34±0.18** 
ns 
8.56 ± 0.27** 
ns 
11.36 
±0.18**ns 
13.24 
±0.18**ns 
Group IV 
STZ+insulin+ EEOA 
(200mg/kg) 
6.46 ± 0.13* 7.67 ± 0.16a 8.54 ± 0.13aa 10.16 ± 0.93aa 
Group V STZ+ insulin 
EEOA (400mg/ 
6.51 ± 0.15* 9.08 ± 0.53aa 10.56 ± 0.38aa 12.31 ± 0.84aa 
 
Table no 13 : Effect of EEOA on Cold waterTail Immerssion test (Thermal allodynia) in 
Experimentally induced  Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared insulin diabetic 
control 
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control group 
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 24 : Effect of EEOA on Cold water Tail Immersion test (Thermal allodynia)  
in   Experimentally induced  Diabetic rat model 
RESULTS: 
The Tail withdrawal latency (Sec) were measured and showed in Table 
no.13 and Fig. no-(24). The Diabetic control (Group 1) showed significant 
reduction in tail withdrawal latency when compared to the insulin diabetic 
control(Group 2). 
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in reaction time when compared to the Diabetic control 
(group 1). 
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Effect of EEOA on Cold Plate test (cold allodynia) 
Experimental 
Croups 
Reaction Time in Sec 
0 Week 4
th
 Week 6
th
 Week  8
th
 Week 
Group I STZ 
(55mg/kg)+vehicle 
11.54 ± 0.27 4.96 ± 0.28 4.48 ± 0.27 4.13 ± 0.12 
Group II STZ+ 
Insulin (5 IU/kg) 
6.23 ± 0.28 ***  6.5 ± 0.92*** 4.46 ± 0.21*** 4.56 ± 0.38*** 
Group III STZ+ 
insulin + 
Pregabalin (15 
mg/kg) 
6.78 ± 0.14** 
ns 
6.98 ± 0.94** 8.56 ± 0.26** 9.78 ± 0.96** 
Group IV 
STZ+insulin+ 
EEOA (200mg/kg) 
6.82 ± 0.27* a 8.78 ± 0.24* 9.17 ± 0.34ns a 9.87 ± 0.34ns  aa 
Group V STZ+ 
insulin EEOA 
(400mg/ 
6.35 ± 0.78ns  
a 
8.31 ± 0.39ns a 
9.26 ± 0.76ns 
aa 
10.13 ± 0.38ns 
aa 
 
Table no 14 : Effect of EEOA on Cold plate test (cold allodynia) in   
Experimentally induced  Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**,***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared insulin diabetic 
control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control. 
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 25 : Effect of EEOA on Cold plate test (cold allodynia)  
in   Experimentally induced  Diabetic rat model 
RESULTS: 
The paw escape latency (Sec) were measured and showed in Table 
no.14 and Fig. no-(25). The Diabetic control (Group 1) showed significant 
reduction in tail withdrawal latency when compared to the normal control 
(Group 1). 
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in reaction time when compared to the Diabetic control 
(Group 1). 
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Effect of EEOA on Tail clip test (mechanical hypralgesia) 
Experimental 
Groups 
Reaction Time in Sec 
0 Week 4
th
 Week 6
th
 Week 8
th
 Week 
Group I STZ 
(55mg/kg)+vehicle 
6.93 ± 0.22 11.23 ± 0.56 11.87 ± 0.53 11.94 ± 0.73 
Group II STZ+ 
Insulin (5 IU/kg) 
11.67 ± 0.64 
*** 
10.26 ± 0.56*** 10.56 ± 0.53*** 10.62 ± 0.73*** 
Group III STZ+ 
insulin + 
Pregabalin (15 
mg/kg) 
7.39 ± 0.13** 
ns 
7.98 ± 0.61** 8.19 ± 0.36** 10.22 ± 0.86** 
Group IV 
STZ+insulin+ 
EEOA (200mg/kg) 
8.73 ± 0.87* a 8.92 ± 0.25* 9.16 ± 0.84ns a 
10.58± 0.22ns  
aa 
Group V STZ+ 
insulin EEOA 
(400mg/ 
8.98 ± 0.54ns  
a 
8.98 ± 0.11ns a 
10.56 ± 0.58ns 
aa 
11.15± 0.18ns aa 
 
Table no 15 : Effect of EEOA on Tail clip test (mechanical hypralgesia)  
in Experimentally induced  Diabetic rat model 
The values were expressed as Mean ± S.E.M (n= 6 animals in each group)     
*,**, ***, indicates significance P < 0.05 , P < 0.01 & P <0.001 when compared insulin diabetic 
control  
a, aa indicates P < 0.05 & P < 0. 01 Significance between diabetic control  
NS indicates Non-significant  
Data was analysed by one-way ANOVA followed by Duncun Multiple range test (DMRT) 
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Figure no 26 : Effect of EEOA on Tail Clip test (Mechanical Hyperalgesia)  
in Experimentally induced  Diabetic rat model 
RESULTS  
The Tail withdrawal latency (Sec) were measured and showed in Table 
no-15 and Fig. no-(26). The Diabetic control (Group 2) showed significant 
reduction in tail withdrawal latency when compared to the diabetic 
control(Group 1). 
Standard (Group 3) and EEOA (200& 400 mg/kg) showed statistically 
significant increase in reaction time when compared to the Diabetic control 
(group 1). 
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Histopathology studies 
 
GROUP 1: (Diabetic control): The nerve fascicle is surrounded by relatively 
thick perineurium. The nerve axons are shrunken. Myelin sheath appears 
fragmented and separated in some fibers. Edema is also noticed in between 
the nerve fibers Other field shows marked thickening of less dense myelin 
sheath in large myelinated fibers with loss of their axons. 
 
 GROUP II: (STZ+ insulin): sciatic nerve is surrounded by the dense 
connective tissue epineurium. Each nerve fascicle is enclosed in the 
specialized connective tissue perineurium. The axons appear clear with 
variable diameters . The myelin is represented by dark ring surrounding the 
axons. 
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GROUP III: (STZ+ pregabalin()): Thick myelinated nerve fibers with intact 
axons (A) surrounded by hypertrophied Schwann cells . The thin myelinated 
nerve fibers have normal appearance  ,edema partly reduced  in the 
endoneurium .  
        
GROUP IV:(STZ+EEPS(200mg/kg )  GROUP V:(STZ+EEPS(400mg/kg))  
Group IV and V receiving group specimen showed most nerve fibers normal, 
with normal nucleus, normal myelin thickness and maintenance of basement 
membrane of Schwann cells. 
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                                              DISCUSSION 
Hyperglycemia must be the originator in the pathogenesis of biabetic 
complications. Diabetes is a heterogeneous set of disorders with a range of 
pathologies and one of the most frequent complications of  diabetes ids 
peripheral neuropathy162. Diabetic neuropathy is characterised by progressive 
chronic neuropathic pain that is tingling and burning in nature with 
hyperesthesia(excessive physical sensitivity, especially of the skin) and 
paresthesia(an abnormal sensation,typically tingling or pricking(pins and 
needels), caused chiefly by pressure on or damage to peripheral nerves) with 
deep aching and it is increased by touch 163. Neuropathic pain is defined as a 
form of chronic pain that results from damage or abnormal function of central 
or peripheral nervous system. The clinical presentation of neuropathic pain 
induces hyperalgesia, allodynia and spontaneous pain164,165. Hyperglycemia 
leads to the toxicity of neurons due to increased glucose oxidation , leading to 
increased reactive oxygen species that may be controlled by the treatment 
with antioxidant.166-168. 
In this study, Ottelia alismoides(L) PERS., extract was given for the 
treatment of neuropathic pain in STZ induced diabetic rats. 
The preliminary phytochemical analysis of EEOA revealed the 
presence of  Glycosides, Alkaloids, Flavonoids, Tannins, Terpenoids, phenolic 
compounds.The tannins, phenols and flavonoids present in the plant Ottelia 
alismoides shows anti-diabetic action. The alkaloids and glycosides present in 
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the herbal drugs are proved to be potent antioxidants as well as 
nephroprotective agent169.   
Acute toxicity studies revealed the non-toxic nature of the EEOA there 
was no lethality or any toxic reactions found with high dose (2000 mg/kg body 
weight) till the end of the study. According to the OECD 423 guidelines (Acute 
Oral Toxicity: Acute Toxic Classic Method), an LD50 dose of 2000 mg/kg and 
above was considered as unclassified so the EEOA was found to be safe. 
In the present study STZ was used for induction of diabetes 
neuropathy in rats. The development of neuropathy was observed at 0 week 
after STZ induction, which was consistent with previous reports170. STZ 
induced diabetic  animal models are most accepted animal models of diabetic 
neuropathy  owing to their reproducibility and reversible diabetes171,172. STZ 
action involved pancreatic DNA alkylation through GLUT2 transporter 
mechanism. Which intern triggers multiple biochemical pathways such as 
polyol pathway, hexosamine pathway, protein kinase C pathway(PKC), 
advance glycation end (AGE) product and poly adipose ribose polymerase 
(PARP) pathway all of these pathways contribute towards oxidative stress by 
generating ROS in a mitochondria results in nerve damage and neuropathy173-
175. Rats injected with 55mg/kg showed significant increase in blood glucose 
levels and decreased nociceptive thresholds. Similar thermal hyperalgesia, 
mechanical and formalin evoked pain in STZ induced rats have been 
demonstrated earlier176,177. Pregabalin a selective Ca 2.2 (α2-δ subunit) 
channel anatagonist and it has has anti neuropathic pain, anticovulsant and 
anxiolytic activities178. Treatment with EEOA extract along with insulin in 
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diabetic rats  significantly increased the nociceptive threshold, decreased 
oxidative stress in a dose dependent manner. 
Before recording the findings on the kidney and liver the effects of STZ 
on the plasma glucose levels and body weights were noted. The observations 
and results of the present study demonstrated that STZ was effective in 
producing severe hyperglycaemia in experimental animals. The animals 
Treated groups II,III & IV appeared ill-looking with loss of their body weights 
because of injurious effects of  STZ  which caused alkylation of DNA and 
produced hyperglycaemia and necrotic lesions179,180. Our in vivo results 
showed that EEPS extract (200 and 400 mg/kg) treatment had an attenuating 
effect on the serum glucose of the diabetic animals with significant 
improvement in body weight it may be due to EEPS persisting insulin 
secretogoge action like sulfonylureas.  
Increase in the weight of kidney (hypertrophy) in STZ treated rats. The 
mechanism of renal hypertrophy is unknown, evidence suggest that local 
alterations in the production of one or more growth factors and/or their 
receptors are crucial to this process181. An increase (hypertrophy) in the 
weight of liver was compared with animals in treated groups. It could be 
attributed to increased triglyceride accumulation leading to enlarged liver 
which could be due to the increased influx of fatty acids into the liver induced 
by hypoinsulinemia and the low capacity of excretion of lipoprotein secretion 
from liver resulting from a deficiency of apolipoprotein B synthesis182. The 
EEOA treated animals were found to have significant increased in organ 
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weights when compared with that of animals with diabetes induced 
neuropathy. 
Oxidative stress is believed to be a biochemical trigger for sciatic nerve 
dysfunction and reduced  endoneurial blood flow in diabetic rats. Persistent 
hyperglycemia disturbs the endogenous antioxidant defense mechanism and 
prevents the free radicals scavenging activity183. In this study the activities of 
various antioxidant enzymes SOD, CAT, GPx, LPO had been found to be 
modulated in diabetic animals. The hyper activities of CAT, SOD could be a 
response of overproduction of H2O2 and free radicals in the diabetic sciatic 
nerve. The significant different in the activities of various biomarkers in 
diabetic versus treated animals indicated the augmented oxidative stress and 
tissue response during diabetes. Moreover nervous tissue is considered to be 
rich in polyunsaturated fatty acids mainly arachidonic acid and 
docosahexaenoic acids which are highly sensitive to LPO and depleted 
antioxidants status. The diabetic animals exhibited the similar biochemical 
imbalance in term of increased LPO levels and decreased GSH levels. 
Hence, these levels revealed the magnitude of oxidative stress and extent of 
structural and functional damage to the nervous system184. 
Diabetes causes increases in the LPO products such as 
malondialdehyde (MDA) or conjugated dienes in sciatic nerves. Scavenging 
free radicals reduced the above effects of sciatic pain models185. In the 
present study EEOA exhibited significant decrease in endogenous antioxidant 
enzyme. This antioxidant activity of the Ottelia alismoides extract could also 
have influenced its activity in diabetic neuropathic pain. 
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Acute hyperglycemia induced by STZ elicits reduction of Na+, K+,  ATPase 
activity. Decrease in sciatic nerve Na+, K+, ATP ase activity could alter the 
normal membrane axon repolarisation after the depolarization induced by an 
action potential. EEOA treatment restored of Na+ K+ ATPase activity. It might 
be possibly improved by inhibition of oxidative stress and also by amelioration 
of vascular  function186s. 
Behavioral studies in diabetic rats often focus on the response to a 
painful or non-painful sensory stimulus, there by measuring hyperalgesia and 
allodynia respectively. The simplest of such tests measures the time to 
withdrawal of a limb such as the tail or a paw from a noxious heat source, with 
a faster withdrawal time being interpreted as hyperalgesia and a slower one 
as hypoalgesia187. In the present study diabetic neuropathy using animal 
models such as thermal hyperalgesia (tail flick, hot water tail immersion, hot 
plate) mechanical hyperalgesia (tail clip method) cold allodynia (cold plate, 
cold water tail immersion) and chemical hyperalgesia (formalin test)188. 
These models are supposed to be behavioural biomarkers of diabetic 
neuropathy. The hot plate and test involves two types of responses paw 
licking and jumping. Both responses integrate at supraspinal structures with 
the C and Aδ type I and II sensitive fibres participating in this model. The tail 
withdrawal (tail flick, tail clip, tail immersion)  respons after thermal stimuli is 
elicited by the spinal motor reflex most probably via endogenous release of 
substance P in the spinal cord189. EEOA extract showed antinociceptive effect 
in the diabetic rats in both hot plate and tail immersion models, which indicate 
that EEOA may act via central mechanism. Cold allodynia (cold plate)  might 
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be caused by disproportionate loss of Aδ fibers and sensitization of cold 
receptors in peripheral neuropathic pain. Impaired blood flow also seems to 
contribute to allodynia190. Vasodilator treatment has been demonstrated to 
reduce allodynia in diabetic rats. EEOA may act on improved neuronal blood 
flow by its direct vasorelaxant properties.  
The nociception induced by formalin is associated with injured tissue. It 
characterised by two phases acute & delayed. The acute phase(0-10min) is 
short lived and initiates immediately after injection and is characterised by C-
fibre activation due to peripheral stimuli. The delayed phase(20-40min) is a 
longer, persistent period caused by local tissue inflammation and also by 
functional changes in the dorsal of the spinal cord. Therefore, this phase is 
inhibited both both by opioids and analgesic agents. Substances that act 
primarily as central analgesic inhibit both phases while peripherally acting 
drugs inhibit only the delayed phase. In the present study the EEOA extract 
exhibited analgesia only in the delayed phase which suggests that the extract 
would possibly prevent the inflammatory markers induced pain perception.   
The H&E stained lateral section of diabetic control sciatic nerve (A) 
showed nerve fascicle is surrounded by relatively thick perineurium. The 
nerve axons are shrunken. Myelin sheath appears fragmented and separated 
in some fibers. Edema is also noticed in between the nerve fibers Other field 
shows marked thickening of less dense myelin sheath in large myelinated 
fibers with loss of their axons compared to  (B). Treatment of Pregabalin and 
Ottelia alismoides (400 mg/kg body weight) in diabetic rats was shown to 
improve the thick myelinated nerve fibers with intact axons (A) surrounded by 
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hypertrophied Schwann cells . The thin myelinated nerve fibers have normal 
appearance  ,edema partly reduced  in the endoneurium in dose dependent 
manner. 
Therefore, Ottelia alismoides extract was proposed that in addition to 
its antidiabetic, the antioxidant properties is the prominent features in 
attenuation of diabetes induced neuropathy and its generating pain. 
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10. SUMMARY AND CONCLUSION 
The present study was to investigate the Neuroprotective effect of 
EEOA in experimentally induced diabetic neuropathy in rats. 
The phytochemical investigation reveals that the presence of tannins, 
phenols & flavanoids are proved to be effective in diabetic treatment. 
Diabetogenic effect of STZ is more reproducible and the metabolic 
changes are much closer to those existing in human diabetes. Hence STZ is 
considered the drug of choice for the induction of experimental diabetes. 
The Blood glucose level significantly decreased with treatment of 
EEOA proves that it has anti-diabetic activity. 
The study shows marked inhibit in oxidative stress by enhancing 
reduced activity of antioxidant enzyme SOD, CAT, GSH, GPx, Na+, K+, 
ATPase & markedly elevate the level of LPO in liver compare to untreated 
diabetic control animals, these findings further strengthen beneficial effect of 
Ottelia alismoides as it showed production against STZ induced diabetic 
neuropathic pain in rats. 
After 4th week, diabetic control has shown signs of neuropathy while 
treated group has showed significant improvement in their condition. From 
this results, it is evident that EEOA has beneficial effect in protective against 
STZ- induced diabetic neuropathy in rats. 
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Histopathological assessment also showed that the damage caused by 
STZ to the sciatic nerve is also markedly reduced by the administration of 
Ottelia alismoides. 
Finally these findings suggest that Ottelia alismoides treatment must be 
beneficial to treat pain in diabetic animals. 
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11. FUTURE PROSPECTIVES  
Further study is required., 
1.  To isolate and separate the active phytochemicals present in the 
ethanolic extract of the Ottelia alismoides (L.) pers. 
2. Formulation of the isolated lead molecule can be designed. 
3. Clinical trial of the formulated molecule in healthy human volunteers 
or diseased persons. 
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